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Abstract
Prostate Cancer (PCa) is the second most diagnosed cancer in men across
the world; it is considered the fifth leading cause of cancer related death
according to cancer statistics 2012. Being a member of the internal parts in
males reproductive system, testing any abnormality with the prostate gland
remains both troublesome and inconvenient, and foremost inaccurate. The
diagnostic practice starts with prostate-specific antigen (PSA) level testing,
which in return is highly indecisive, provoking an over diagnosis and treat-
ment.
Genomic alteration and Single Nucleotide Variants (SNV s) are assumed to
play a role during PCa progression. On behalf of the RIBOLUTION project,
a project with the aim of finding diagnostic biomarkers from RNA sequences,
SNV s in RNA sequences were analysed to pinpoint potential candidate genes
in PCa. The fact that the cohort provides whole-transcriptome data of pro-
static tissue promotes the possibility to obtain comprehensive knowledge of
the cancerous changes. The advantage of detecting SNV s in RNA sequences
relies in focusing on only those, which could be relevant to the gene’s func-
tion. However, methods for detecting and analysing SNV s solely in RNA
sequences are currently not yet established.
This study aimed to (1) establish fitting and applicable assays to identify,
inspect and conclude the potential role of SNV s in RNA sequences, (2) use
the obtained knowledge to single out the genes that are potentially relevant
for PCa.
SNV s in the RIBOLUTION cohort were investigated. Prostate tissue was
obtained from 40 PCa patients, and then RNA was sequenced using Next
Generation Sequencing. In 16 patients, a pairwise prostatic tissue was taken,
one a confirmed tumor tissue and the second a tumor-free tissue. As a
control, samples from 8 men with benign prostatic hyperplasia were likewise
sequenced.
Different computational pipelines were established and successfully fulfilled
the aim. The CVR Module (Calling Variants in RNA-Seq) is a computer-
based pipeline intended to identify SNV s and discriminate between false
positive and true positive calls. Validating the SNV s reported by the accom-
plished Module has shown high sensitivity (> 80% validated SNV s). Much
as novel SNV s that had ∼ 101% higher median calling quality in comparison
to SNV s found in dbSNP, the Single Nucleotide Polymorphism Database.
In agreement with current knowledge, novel SNV s was observed in tumor
samples with slight but significant increase vs. tfree tissue (P < 0.05, testing
on proportion). On top of that, positive correlation between non-silent effect
and novel SNV in tumor samples was also observed (P < 0.05, r = 0.33,
Pearson’s correlation). Moreover, more than 40% of the candidate genes
were found in COSMIC, the Catalogue Of Somatic Mutations In Cancer;
some of them are confirmed somatic mutation (cancer associated). About
11% were also reported in studies to be disease associated or observed in
other diseases, mostly heredity related.
Potential PCa associated genes were identified via combination of three differ-
ent systematic methods: mutational clustering, mutational functional bias,
and covariates of the mutated genes. The first method (mutational cluster-
ing), however, did not reveal any significant insight. The top candidate genes
were then selected in accordance with the latter methods. The list of top can-
didate genes includes > 50% genes with direct association with PCa; > 80%
genes previously reported in other cancer types, while ∼ 35% that are in-
volved in PCa associated complexes. Besides well known and validated PCa
biomarker (alpha-methylacyl-CoA racemase (AMACR)), we identify for the
first time, from mutational prospective, 22% of the genes to be potentially
associated with PCa. Among those, one of the most promising candidate
genes is NWD1 (NACHT and WD repeat domain containing 1). This gene
was mentioned in a previous study to be a potential player in PCa progno-
sis. We add to this our novel observation, NWD1 was found significantly
mutated in the entire tumor samples. These significant findings were proven
to be tumor-specific when they were compared to the available control and
tumor-free (P < 0.05, non-parametric ranking).
We conclude that analyzing SNV s from RNA is as useful and informative as
DNA-based ones, and accomplish further benefits that could be gained once
the suggested methods are adapted.
Zusammenfassung
Prostatakrebs (PCa) ist weltweit der zweitha¨ufigste Krebs bei Ma¨nnern und
die fu¨nfha¨ufigste krebsbedingte Todesursache, laut Staistiken von 2012. Die
regelma¨ßige Untersuchung der Prostata, als Teil des ma¨nnliche Fortplan-
zungssystems, auf Abnormalita¨ten ist fu¨r den Patienten unangenehm und
vor allem ungenau.
Der diagnostische Test auf PCa umfasst die Messung des Prostata-spezifischen
Antigens (PSA). Leider ist die Aussagekraft des Tests ha¨ufig unklar und kann
daher zu unno¨tigen Behandlungen fu¨hren.
Es wird angenommen, dass genomische Vera¨nderungen und Einzelnukleo-
tidvariationen (SNV s engl. Single Nucleotide Variations) Einfluss auf die
Progression von PCa haben. Im Rahmen des Projekts RIBOLUTION , das
auf die Identifikation von diagnostischen Biomarkern aus RNA Sequenzen
ausgerichtet ist, wurden SNV s in RNA Sequenzen analysiert, um potentiel-
le Kandidatengene in PCa zu ermitteln. Aufgrund des Vorhandenseins der
kompletten Transkriptomdaten fu¨r die Prostatagewebe aller Patienten die-
ser Kohorte ist es mo¨glich umfassende Erkenntnisse u¨ber die krebsbedingten
A¨nderungen zu erlangen. Der Vorteil der Detektion von SNV s in RNA Se-
quenzen liegt in der Mo¨glichkeit der Fokussierung auf die SNV s, die relevant
fu¨r die Genfunktion seien ko¨nnten. Allerdings existieren bis dato keine Me-
thoden fu¨r die Analyse von SNV s auf Basis von RNA Sequenzen.
Diese Studie zielte darauf ab, (1) Assays zur Identifizierung, Validierung von
SNV s aus RNA-Sequenzen sowie deren potenzieller Funktion zu etablieren.
(2) Die gewonnenen Erkenntnisse wurden verwendet, um Gene zu identifizie-
ren, die potentiell Einfluss auf PCa haben.
Es wurden SNV s innerhalb der RIBOLUTION -Kohorte untersucht. Diese
Kohorte umfasst 40 Patienten mit PCa aus deren Prostatagewebe RNA iso-
liert und sequenziert wurde. Bei 16 Patienten wurde sowohl Tumorgewebe als
auch Tumor-freies (Tfree) Gewebe sequenziert. Als Kontrolle wurden Proben
von 8 Patienten mit positiver gutartiger Prostatahyperplasie sequenziert.
Zur Auswertung wurden verschiedene Pipelines aufgebaut.Das Modul CVR
(Calling Variants in RNA-Seq) ist eine Pipeline, die dazu dient, SNV zu
identifizieren und falsch-positive und echt-positive SNV s zu unterscheiden.
Die Validierung der von CVR identifizierten SNV s, zeigte hohe Sensitivita¨t
(> 80% validierter SNV s). Ebenso zeigten neu identifizierte SNV s eine ∼
101% ho¨here median calling quality im Vergleich zu SNV s aus dbSNP
(Single Nucleotide Polymorphism Database). U¨bereinstimmend mit derzei-
tigem Kenntnisstand wurden neue SNVs signifikant ha¨ufiger in Tumorproben
idnetifiziert (Tumor vs. Tumorfreies-Gewebe (P < 0.05, Hypothesentests fu¨r
Proportion). Es konnte eine positive Korrelation zwischen nicht-stillen Ef-
fekten in Tumorproben beobachtet werden (P < 0.05, r = 0.33, Pearson
Korrelationskoeffizient). Außerdem wurden mehr als 40% der Kandidaten-
gene in COSMIC gefunden, Catalogue Of Somatic Mutations In Cancer.
Von diesen sind einige somatische Mutationen als krebs-assoziiert besta¨tigt
wurden. Etwa 11% sind krankheitsassoziiert oder stehen im Zusammenhang
mit Erbkrankheiten.
Potenziell PCa assoziierte Gene wurden durch Kombination von drei ver-
schiedenen systematischen Methoden identifiziert: Mutations-Clustering, Mu-
tationsfunktions -Bias und Kovariaten der mutierten Gene. Die erste Me-
thode (Mutations-Clustering) ergab keine signifikanten Ergebnisse. Die Top-
Kandidaten-Gene wurden dann gema¨ß der letzteren Verfahren ausgewa¨hlt.
Die Liste der Top-Kandidatengene schließt > 50% der Gene mit direkter
Assoziation mit PCa ein, > 80% der Gene sind bereits aus anderen Krebs-
typen bekannt wa¨hrend ∼ 35% an PCa assoziierten Protein-Komplexen be-
teiligt sind. Neben dem bekannten und validierten PCa Biomarker (alpha-
Methylacyl-CoA-Racemase (AMACR)) identifizierten wir erstmals, aus mu-
tationaler Perspektive 22% der potentiell PCa assoziierten Gene. Unter die-
sen ist NWD1 (NACHT and WD-Repeat domain containing 1) der inter-
essanteste Kandidat. Dieses Gen wurde bereits in einer fru¨heren Studie in
Zusammenhang mit der Prognose von PCa gebracht. Wir unterstu¨tzen diese
Beobachtung, da NWD1 in allen Tumorproben signifikant mutiert vorgefun-
den wurde. Dieses Ergebnis ist tumorspezifisch, wenn es mit der verfu¨gbaren
Kontrolle und tumorfrei Proben (P < 0, 05, nicht-parametrisches Ranking)
verglichen wurde.
Wir schließen daraus, dass die Analyse von SNV s aus RNA-seq Daten genau-
so nu¨tzlich und informativ sein kann wie aus DNA-seq Daten. Des Weiteren
kann es zusa¨tzlich Vorteile bieten, wenn die verwendeten Methoden entspre-
chend angepasst werden.
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1 Introduction
1.1 Prostate as Part of Male Reproductive
System
The Male Reproductive System consists of two parts, the external genital
organs (scrotum & penis), and the internal genital organs (vas deferens,
epididymis & glands). The glands are: prostate gland and cowper gland
(aka bulbourethral gland).
The prostate gland is located behind the pubic bone and below the urinary
bladder, and produces ∼ 30% of the seminal fluid. The fluid produced by
the prostate gland is colorless, thin, and has pH level of 6.4, which is as-
sociated with fertility (sperm motility is influenced positively by high pH
level). Moreover, it contains immunoglobulin, prostaglandins, acid phos-
phomonoesterase, and spermine, which are a set of proteins and enzymes
that collectively gives the volume, odor, and nature of the fluid. Most im-
portantly, the secretion produced by the prostate contains prostate specific
antigen (PSA). Any disorder in the male reproductive system changes these
properties and the concentration of these compound, and consequently the
fertility of a man [65,111].
The gland has three main zones: transition zone (5% of the prostate volume),
central zone (25% of the gland volume), and peripheral zone which occupies
the remaining volume of the prostate (see Figure 1.1).
The normal size of the prostate gland is approximately as small as a wal-
nut. However, the size increases while aging (see Figure 1.3.a), which causes
different problems such as frequent, painful and/or urinating difficulty. The
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Figure 1.1: Prostate Gland
Across cut of the prostate gland [111] shows the main three zones, penile
urethra (membranous urethra), ejaculatory ducts and the other components.
enlarged prostate gland (abnormal) is termed as benign prostatic hyperplasia
(BPH ), a sort of prostate disorder that almost every elderly man encounters
(70s). BPH tends to occur in the transition zone tissue. On the other hand,
development of malignant growth (cancerous) is observed mostly in the pe-
ripheral zone [111].
1.1.1 Prostate Cancer (PCa) and Diagnosis
Prostate cancer (PCa) is the most common cancer in non smoking males.
Clinical observation indicates that PCa occurs in most instances between
elderly men. Although that the number of recorded cases is notably risen
[13, 37], the risk factors remain broadly unknown. However, several factors
are believed to convey to PCa, such as age, ethnicity, family history and
PSA level [114, 128]. For instance, African American men have higher PCa
risk than Whites and Asians [108]. While heredity and family history has
been observed rapidly in different cohorts of various ethnic background [19,
61,118,170].
Since PCa is strongly associated with age, it became evident that almost
every elderly man (> 70 years of age) has a sort of prostate disorder, which
urges the need to find a correct diagnostic procedure and, hence, increase the
capability to distinguish critical cases from other cases.
The clinical diagnosis starts once the physician could detect any sort of any
2
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protrusions or abnormality in size of the gland via DRE procedure (Figure
1.3.b). If the results of this finding combined with PSA level were suspi-
cious, the assistance of magnetic resonance imaging (MRI) and transrectal
ultrasound-guided prostate biopsy will be carried out (Figure 1.3.c). From
the obtained biopsy, Gleason score is computed (number of cancer cells).
Following this basic approach, the cancer stage could be determined, i.e.
the higher the score the more aggressive the cancer is and could have worse
prognosis [128].
One way to plan the suitable treatment cancer staging should reflect the
anatomic extent of the disease. Therefore, the TNM Classification of Ma-
lignant Tumors (TNM) is used as scaling system to classify the stage of
PCa.Tables 1.2 and 1.1 were originally published in [127], in which, cancer
is classified into three main categories: Primary tumor (T), nearby lymph
nodes (N), and metastasis (M), each of which has its subcategories. The
TNM classification scale aims to assist diagnosis, prognosis, choosing appro-
priate treatment, and accurate follow up [127].
Table 1.1: Classification of Tumor Stages. The classification of cancer by
anatomic disease extent according to [127], where the stages of regional
(nearby) and distance tumor are shown.
Regional Lymph Nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distance Metastasis
M0 No distant metastasis
M1 Distant metastasis
M1.a Non-regional lymph node(s)
M1.b Bone(s)
M1.c Other site(s)
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Table 1.2: Classification of Tumor Satges. The classification of cancer by
anatomic disease extent according to [127], where primary tumor and its
different stages are shown.
Primary Tumor
Stage Description
TX Primary Tumor cannot be assessed
T0 No evidence of primary Tumor
T1: Clinically in apparent Tumor, neither palpable nor visible by
imaging
T1.a Tumor incidental histological finding in 5% or less of tissue
resected
T1.b Tumor incidental histological finding in 5% more than of tissue
resected
T1.c Tumor identified by needle biopsy, e.g., because of elevated PSA
T2: Tumor confined within prostate
T2.a Tumor involves one-half of one lobe or less
T2.b Tumor involves more than one-half of one lobe, but not both
lobes
T2.c Tumor involves both lobes
T3: Tumor extends through the prostatic capsule
T3.a Extracapsular extension (unilateral or bilateral) including mi-
croscopic bladder neck involvement
T3.b Tumor invades seminal vesicle(s)
T4 Tumor is fixed or invades adjacent structures other than seminal
vesicles: external sphincter, rectum, levator muscles, and/or
pelvic wall
Figure 1.2 depicts the stages of primary tumor. In stages 1 (T1) the first
formation of cancerous cell within the prostate gland. However, it is unable
to be felt or seen. In stage 2 (T2) the tumor is still local but growing,
hence, it could be felt and seen. Depending on which direction the growth
takes, the first symptoms might vary. For example, if the growth was in the
direction of urethra then the patient might start having painful, burning and
frequent urinating along with weak flow of urine. The symptoms might also
include erection or ejaculation difficulty. These symptoms, however, could
be mistaken with other prostate disorders (e.g. BPH , prostatosis ).
The advanced stages T3 and T4 constitute the stage in which the tumor is no
more confined within the gland, and could have metastasized to the nearby
4
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tissues such as lymph nodes, bladder, or bones. At this point, the symptoms
became more severe, the following symptoms are common in these states of
cancer prognosis: loss of or difficult erection, painful ejaculation, blood in
semen or urine, and stiffness in the lower back, hips, or upper thighs.
The tumor in these stages is detectable by multiple methods, all together
assist to determine the Tumor extent, usefulness and efficiency of treatment
[112,114,127,128,140].
T2 
Stage 
T3 
Stage 
T4 
Stage 
T1 
Stage 
Lymph 
nodes 
Bladder 
Bladder Bladder 
Bladder 
Figure 1.2: Primary Tumor Main Stages
The main stages of Tumor is are illustrated, where in early stages, namely
T1 and T2, PCa could go unnoticeable, as the patient has usually no broad
symptoms or complains. The advance stages of PCa, T3 and T4, cause
noticeable problems to the man. The advanced stages are normally detected
by DRE (see Figure 1.3.b)
The standard PCa clinical diagnosis according to the European Society For
Medical Oncology [128], the European Association of Urology [114] and the
National Comprehensive Cancer Network [112] consists of the following steps:
Prostate-Specific Antigen (PSA) :
PSA is a glycoprotein enzyme which is secreted by the epithelial cells of
the prostate gland. In contrast to normal healthy prostate, where PSA
exists in small quantity, PSA elevates when the prostate abnormal is.
Considering that the diagnosis of PCa was only confirmed in 30% of
abnormal prostate after taking biopsy (frequently false positive), makes
it a method for cancer detection but not for mortality diminishing [168].
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Digital Rectal Examination (DRE) :
The rectal exam is originally intended to detect any Tumor in the rec-
tum, prostate, acute abdominal symptoms, and other similar disorders.
In comparison to PSA, DRE can miss more Tumors in the early stages
of PCa, therefore, it is usually combined with blood test and multiple
pinholes (Figure 1.3.b).
Ultrasound Biopsy :
The procedure of Ultrasound-guided prostate biopsy is only proceeds if
highly suspicious signs were seen by the physician. The procedure may
be applied through the urethra (transrectal ultrasound-guided prostate
(TRUS) ) or through the perineum. Firstly, suspected areas in prostate
gland are marked and then targeted by a thin needle in a systematic
manner. The side effects observed when following TRUS by most pa-
tients are less dramatic. Typical side effects include bloody urine in
the next 2-3 days, bloody semen for the following eight weeks, and a
burning feeling when urinating (Figure 1.3.c).
Treatment :
Treatment is decided based on the state of cancer advance, age, and
medical history. If prostate enlargement became a hinder, surgical
procedure might become an option. However, if the cancer has widely
extended outside the gland, the likelihood decreases that the cancer is
treatable. Therefore, it could be decided that the patient should be
spared the extra trouble and consequences of the surgery. Going under
the knife is only recommended when the cancer is confined within the
gland (T1,T2 & T3) [70]. Generally, there are two types of surgeries:
the Nerve Sparing and the Non-Nerve Sparing (Figure 1.3.d).
Moreover, radiation therapy, and androgen deprivation therapy could
also be part of the treatment or part of the follow up to the radical
procedure. Chemotherapy, on the other side, is given if the patients
encounter neuro-endocrine changes [128].
The unfortunate potential consequences of PCa treatment could be very bru-
tal to the patients, and sexual function, infertility, and additionally urinary
problems are the main side effects. Some of these side effects are temporary,
yet they could last for years after treatment till the function is fully retained
to the pre-treatment time. For instance, in case of nerve-sparing surgery,
50 − 60% of the patients suffer from erectile dysfunction, but 30 − 60% of
them might regain the normal erectile function back within two years after-
wards.
The follow-up after successful treatment should combine DRE, PSA and
6
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repeated biopsies all together. However, the interval span is yet to be deter-
mined (personalised medicine).
The survival rate of PCa treatment in early stages ranges between 70−80%,
while it drops to 40− 60% in the advanced stages [114].
1.2 Aim
1.2.1 Identification of SNVs in RNA-Seq
This work aims to establish a valid variants-calling scheme solely from RNA-
Seq data. The fact that since the importance of SNV s met the eye, DNA
based methods were till recently the only well established and developed ones.
This increasingly triggered the need to establish RNA approaches, that can
help in return, understanding further aspects to mutational effect. The de-
veloped module CVR identifies potentially true positive SNV s by eliminating
the source of error as possible as it goes. Quantity and quality besides other
constraints are used to fine-tune detected SNV s.
The plausibility to compare CVR outcome with known other resources gave
further evidence of its accuracy, especially that over 80% of detected muta-
tions were already identified by at least one external resource (e.g. COSMIC,
dbSNP, publications, etc.) .
In this work, the terms variants and mutations are used interchangeably.
1.2.2 Enrolment of SNVs in PCa
According to GWAS studies (catalogue 2008-end of 2014 [171]) the associa-
tion between SNPs PCa has been shown in at least 39 studies the association
between SNP and PCa. These studies have shown that employing the muta-
tional aspect can improve the current diagnostic measurements and increases
its accuracy. Interestingly, it has been shown that the sensitivity and speci-
ficity of PSA test is subjected to the mutational spectrum of PCa. Therefore,
the time could have come to convey genetic alterations (e.g. SNPs or SNV s)
in the standard clinical along with the current tests (see Figure 1.3).
Due to the nature of RIBOLUTION cohort, this work addresses the muta-
tional spectrum of PCa in a quantitative manner in order to highlight mostly
mutated genes and use SNV s to estimate the likelihood of better PCa diag-
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nosis or risk factors. Identifying driver variants are not covered within the
scope of this study (see Chapter 5).
Thesis Structure
In this chapter, the enigma of PCa diagnosis has been introduced together
with a statement of the chief goal and prerequisites of this work.
Chapter 2 gives the fundamental biological backbone to this essay.
In chapter 3, an intensive review is given to the commonly used practices,
computational methods, and data infrastructure.
The established groundwork is explicitly explained in chapter 4. In which,
the formerly introduced computational methods and practices blend together
and are successfully adapted to match the nature of the biological materials.
Over and above, the main results of applying the newly adapted pipelines
(foremost The CVR module) are given and utterly extended in the Appendix.
In like manner, the technical steps are given briefly in the Appendix as well.
The discussion of the findings and the limitations of this work is given in
chapter 5.
Finally, the concluded inside story is told in chapter 6.
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(a) From normal to abnormal [1]
Prostate 
Transrectal biobsy 
Needle 
Rectum 
Bladder 
Ultra 
probe 
(b) DRE [1] (c) Transrectal biopsy [1]
(d) Prostate Surgery
Figure 1.3: PCa Diagnosis and Treatment
(a) enlargement of prostate gland is a normal phenomena by elderly men
known as benign prostate Hyperplasia (BPH ). PCa Diagnosis (b-c), Digital
Rectal Exam (DRE) is typically done by the physician to test prostate size
or any sort of abnormality. (d) Prostatactomy picture taken from RIBOLU-
TION Archive. [1] http://www.cancer.gov/types/prostate/patient/
prostate-treatment-pdq. 9
2 Biological Background
2.1 The Cell Central Dogma
In order to keep life go on, every living organisms have classes of cells,
which are capable of storing, decoding and passing on the genetic message
to its descendants. The genetic message (genes) is encoded into sequence of
nucleotides forming the subunits of DNA, which in return takes the shape of
twisted double stranded molecule (double helix). The nucleotides bases are:
cytosine (C), thymine (T), and uracil (U) which are called pyrimidines. In
addition to the former nucleotides, genetic information is also encoded via
adenine (A) and guanine (G) which are called purine [6].
Both the genetic message and its decoding spectrum within the organisms
are the key to the genomic diversity between all forms of life. The decoding
mechanism (The Cell Central Dogma), in Eukaryote, Bacteria and Archaea,
consists of three main steps namely: transcription, translation and protein
synthesis (Figure 2.1 shows these steps in eucaryotic cell). Nonetheless, its
complexity varies significantly between species [2].
The Cell Central Dogma is the process of reading genes out of the DNA into
RNA to produce proteins. Each gene is transcribed and then translated in
different quantity, which is sustained by different intra/extra-cell factors. Cell
type, tissue of the organ along with the intended function are also some of
the main factors influencing which gene to express in which quantity, so that
the cell is capable of regulating the level of gene expression at any time [2,6].
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2.1.1 From DNA to RNA
In eucaryotic cell, transcription takes place in the nucleus. However, protein
synthesis happens in the cytoplasm (see Figure 2.1).
Transcription is the process in which, one strand of DNA is read by RNA
polymerase (RNAP) to produce a premature RNA (pre-mRNA) which might
be later used in translation
The main differences between DNA and RNA are:
• RNA is single stranded.
• The sequence alphabet of RNA consists of A,C,G,U, while in DNA
A,C,G,T.
• Nucleotide subunits in RNA are rather ribonucleotides, i.e. sugar ri-
bose, than deoxyribose.
These minor changes lead to the major difference in the structures of RNA
and DNA. Remarkably notable, the number of possible forms the structure
of one RNA is exponential to its length [63]. Being single stranded, RNA has
significantly large scale of bend-ability, which grants it in return, the large
functional spectrum.
The expressed RNA in any cell, reflects the actual picture of its metabolism.
When a new pre-mRNA is produced it speaks for the genetic information of
one gene. Interestingly, the different transcribed RNAs could serve as regu-
latory, and infrastructural parcels in the cells [106].
Since protein is the building block of any chemical activity in a living cell,
it was not possible to spot the outcome or the importance of that process.
Therefore, it was assumed that any process did not yield protein is transcrip-
tion noise or ”junk DNA”.
Both the importance and the functionality of these none protein coding parts
has been gradually and partially elaborated [105, 106]. Thus, the term junk
DNA, has been changed into ”non-coding RNAs” (ncRNAs).
For the reason that the role of ncRNAs is yet to be understood, investigating
the role of genetic variations in those regions is not trivial. Moreover, given
that the regions of ncRNAs are known for its susceptibility to obtain genetic
alterations, it adds additional challenge to distinguish between functional
SNV s, dysfunctional and silent ones. Therefore, analysing genetic variation
in the non-coding parts of the genome is not enclosed within the scope of
this work.
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Figure 2.1: From Transcription to Protein Synthesis in eucaryotic [6].
Clearly, transcription takes place inside the nucleus. Once the mRNA is
capped and poly-A tail was added, it is then transformed through the nucleus
pores into the cytoplasm where translation can start. Exonic and intronic
regions are clearly illustrated. Classically, to address the association between
suspicious variant and a disease, identification of the disrupted process in the
mutated genes is done in a backward manner.
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More into The RNA
While transcription is still proceeding, the growing outcome chain consists of
exons and introns mix. Depending on the intended purpose, different RNA
processing steps are carried away (see Figure 2.1).
If the gene was transcribed to produce mRNA, three main processes are
applied in the following order [6]:
1. RNA Capping: once the produced RNA reaches 25 nt in length, cap-
ping the 5’ end of it starts. Capping procedure is adding the methylated
aguanine (G), an aberrant nucleotide, to the first synthesized end of
RNA.
2. RNA Splicing: introns are cut out and exons are joined together.
Keeping in mind that the same gene could be spliced in many differ-
ent ways and that the resulted transcripts could have different protein
product and some with no protein product (for the least a known one).
3. Polyadenylation: as the name indicates, polyadenylation adds a chain
of adenine (A) one after another to the 3’ end of mRNA.
Once the transcription is done and these three steps are successfully com-
pleted, stabilized mRNA is finally formed and, therefore, is ready to be trans-
mitted to the cytoplasm where protein synthesis will take a place.
There are several types of RNA which are transcribed for other purposes than
being a mRNA. For example, those RNAs are Ribosomal RNA, transfer RNA,
small RNAs (e.g. snoRNA, microRNA), and others.
2.2 Genetic Variations
The human genetic variations can be divided into several categories. Pre-
sumably, the structural variations, and single point variation.
The structural variation is a type of alteration in the chromosome, that
causes gene instability. Typically, a stretch of length that can reach up to
3Mb is trans-located, inverted, inserted, deleted or/and many other similar
alterations. A large well studied subclass of structural variations is the Copy
Number Variations (CNV ). Which is by definition is plausibly detectable
on DNA level, since CNV is copying a slice of DNA more than expected
or being deleted, which results from unequal chromosome re-combinations
13
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events. When it happens in a population, its is then called Copy Number
Polymorphism (CNP).
The second type of genetic variation happens when single nucleotide is substi-
tuted by another. Single Nucleotide Variations (SNV s - pronounced ”sniv”)
are the most common kind of genomic variations. In like manner, single
nucleotide polymorphisms (SNPs) are SNV s observed within a population.
This quantitative presence is the major ground for using them as markers in
genes mapping studies [6, 185].
Table 2.1 highlights some of the recognized wet-lab methods to identify and
genotype SNPs, while section 2.2.1 sheds the light on the technical and bio-
logical origins and consequences of SNV s.
In this study, only SNV s are analysed, since other type of genetic variations
are by definition unsuitable to analyse using solely RNA, e.g. short tandem
repeats (STR) and CNV (see Section 5.1.2.1 for further details).
2.2.1 Single Nucleotide Variants (SNVs)
It has been estimated that a single base substitution can occur every 1000
nucleotide in the human genome, making individuals differ from each other
at least 0.1% in their genomes [6, 34].
Single nucleotide variant could emerge from both biological and technical
sources. Known biological causes are unrepairable DNA damage [142], evo-
lution necessity [18, 144] and inheritance. While technical causes could vary
from sequencing error, incomplete reference, mapping error, to variant callers.
Some of these errors are addressed in this work, a snapshot of the possible
erroneous sites were taken and briefly explained in Section 8.2.4.
SNV could lead to a disruptive consequences, beneficial adaptation, or unno-
ticeable effect [42]. The well known SNV classification is rooted to their func-
tional consequences. That is, a SNV is either synonymous or non.synonymous:
• Synonymous SNV : or the silent variant! Synonymous SNV indicates
the case where a mutation occur in the protein coding part of the gene,
and therefore, the effect on the coded protein could be measured. In
this case the effect does not change the final coded protein (see Figure
2.2.a).
• Non-Synonymous SNV : while synonymous SNV does not change
the coded protein, non-synonymous SNV , contrariwise, have a notable
14
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effect on the final protein (see Figure 2.2b-d). Under this class there
are other main subclasses, for instance:
– Missense: this type of consequence could results in different pro-
tein or even a malfunctioning one, as the single base change alters
the amino acid of the frame being read.
– Nonsense: a more sever effect where the encoded codon is re-
placed by stop codon resulting in a premature stop codon.
Tables 8.2 and 8.2 give more detailed explanation of SNV effects.
Owing to the quantitative presence of SNV s, its is practically neither rea-
sonable nor cheap to investigate every SNV : first, to distinguish the false
positively identified ones. Second, to measure its functional effect, especially
the majority of SNV s are randomly acquired and usually accumulate during
individual lifetime [125]. Therefore, in the last decade, many computational
methods were established and developed to predict SNV effect taking into
account many factors (e.g. locus information). Some of these methods are
explained in Chapter 3 (particularly Section 3.3.3).
Moreover, due to the molecular mechanisms, the single base substitution
(SBS) can take two forms:
• Tv: SBS could alternate the organic compound of the molecular struc-
ture from two groups of nitrogenous bases to one group, or visa verse.
This chemical alteration is known as transversion.
• Ti: SBS does not change the number of nitrogenous rings, i.e. 1-to-1
ring, or 2-to-2 rings. This chemical alteration is known as transition
(see Glossary:SBS).
Although that Tv has 4 possibilities while Ti has only 2, it has been seen that
Ti occurs oftener than Tv especially in the coding parts of the genome [181].
Accordingly, the bias towards Ti or Tv is spatial dependent [75]. This is due
to the expense of the chemical change, which takes into account the distances
between base pairs within DNA polymer.
The ratio (%) is typically computed by total number of Ti incidents divided
by total number of Tvs (see Equation 2.1) [177].
% =
∑
]Tv∑
]T i
(2.1)
The observed ratio % ranges usually between 2-2.5 in coding regions, and can
reach up to 3 in CDS regions.
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Met Lys Ser Leu 
ATG  AGT  TTG  AAG  GAG  TAA  
Glu Stop 
mRNA Seq 
Met Lys Ser Leu 
ATG    AGC  TTG    AAG  GAG    TAA  
Glu Stop 
Met Arg Ser Leu 
ATG    AGT  TTG    AGG   GAG    TAA  
Glu Stop 
Met Stop Ser Leu 
  ATG  AGT   TTG   TAG        GAG   TAA  
Glu Stop 
Met Lys Ser Leu 
  ATG  AGT   TTG     AAG  GAG   CAA  
Glu Gln 
a) 
b) 
c) 
d) 
AA Chain 
Figure 2.2: Single Nucleotide Variations
Single Nucleotide Variations (SNV ). Four different theoretical cases illustrate
the effect of SNV on the produced protein. In the middle, the sequence
of the original mRNA and its amino acid (AA chain) are shown, while in
each corner different impact is illustrated. a) a synonymous variant, where
there is no effect on the final amino acid (Proteins Primary Structure). This
kind of position alteration on sequence level is considered silent. b) a non-
synonymous variant, specifically called: missense variant as the amino acid
is indeed modified and, therefore, could lead to different protein isoform,
or completely useless product (Proteins Secondary Structure). It could also
deactivate the the entire function. c) a nonsense variant, another subclass of
a non-synonymous modification. The nonsense variant induces a stop codon
in the middle of mRNA sequence. Such modification is considered highly
disruptive since the functionality is directly influenced by this bold change.
Likewise, d) is another non-synonymous modification where the stop codon
is lost. The effect of such modification is as sever as the nonsense one.
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Knowing the chemical landscape of the genomic region is another represen-
tation to the potential effect of the SNV s.
More into SNV s Effect
Each SNV could be addressed using different scales. In Table 2.2, each scale
refers to the main steps in the central cell dogma: DNA Position is the coor-
dinates of the SNV before transcription. cDNA Position is the coordinates
of the SNV in the resulted transcript. Finally, AA Protein Position (Amino
Acid) refers to the position of SNV in the protein product if the RNA was
translated (see Section 2.1).
2.3 Genetic Variations and Cancer
The naive definition of cancer is the uncontrolled abnormality growth
of cells. Despite the overwhelming acceleration in cancer studies, the rules
which regulates the transformation of normal cell into abnormal one and
eventually into malignant cancers, are yet to be addressed. Those rules dis-
rupt the cell molecular machinery starting with proliferation, differentiation,
and finally death.
Consequently, cells do not follow their normal proliferation path and, there-
fore, end up clonally expand. The proliferation process is referred to by
DNA Replication, as every time the eukaryote cell divides its DNA has
to be replicated. Despite its fidelity and devotion, realistically, DNA repli-
cation is not a perfect process. While transmitting billions of nucleotides
to the daughter cells (' 3 billion [142]) errors could happen regardless of
the various DNA repair chores. Moreover, it became evident that develop-
ing cancer involves continuous forceful genomic changes that vary between
cancer types [6, 57,58].
When it comes to cancer studies, SNV s are particularly important, as they
may involve in tumor prognosis. The question is, how to discriminate between
passenger mutations, those who occur randomly with absolutely no effect,
and driver mutations, those who have disruptive presence and rise the risk
to turn into cancerous cell. A wide colourful assays have been developed in
the last recent years which aim to address this particular issue. Section 3.3.4
explains the methods used in this work.
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Table 2.2: Different Positions Coordinates of the SNV . Five different cases of
SNV are laid out in Table 2.2. Each case illustrates different case and com-
plete spatial information using three different biological scaling (the SNV s
are taken from tumor samples in HRP). Theoretically, the effect of SNV s
could be seen in Figure 2.2, where the AA alteration of each one of these
SNV s is visualized.
Besides its genomic position, V ar1 has one further appearance on RNA level.
Since its RNA is not translated, there is no further available information.
V ar2 is an example of a synonymous variant, because the amino acid re-
mains intact. In 2.2.a, the case is depicted where the underlying mRNA
sequence is indeed different. V ar3 is an example of a non-synonymous vari-
ant, where the amino acid changes from Lysine (K) to Arginine(R). V ar4
is another non-synonymous variant, where an induced stop codon replaces
Lysine. In this case the translation will be cut prematurely and, hence, the
resulted protein might be functionally disruptive. V ar5 is the opposite sit-
uation to V ar4, the stop codon was replaced by Glutamine. In this case,
the resulted protein is longer than intended and, hence, could also lead to a
disruptive function.
SNV Chromosome DNAPosition
cDNA
Position
AA +
Protein
Position
Figure
2.2
V ar1 1 16902856 1567 - -
V ar2 1 120166681 405 S95S a
V ar3 1 53153432 696 K219R b
V ar4 1 155365340 2346 K2005* c
V ar5 6 32796685 2191 *687Q d
The complexity of tumorigenesis appears to involve multistep genomic al-
terations. Several studies have shown the mutational effect spectrum (e.g.
[17,23,43,160,176]). The mutational accumulation during every phase in cell
cycle makes it almost impossible to detect and repair or reverse. As a conse-
quence, when a damaged-DNA carrier cell proliferates all its daughter cells
will carry these mutations and may in return acquire their own. A damaged-
DNA carrier cell could also be of a type that give rise to gametes, which
has been addressed by heredity risk factor. Many cancer types have been
correlated to hereditary genomic alteration including prostate cancer [166]
(see Section 1.1.1). Moreover, it has been shown repeatedly, that these mu-
tations target genes involve in repair mechanism and tumor suppressing, a
well known example is p53 [20].
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Figure 2.3: Intra-tumor Heterogeneity
Cancer growth as evolutionary somatic process [142]
2.3.1 Intra-Tumor Heterogeneity
DNA damage could be modelled as a stochastic model, in which the genomic
alterations occur randomly and are caused by several agents. The second
model is far from being stochastic as the genetic variations resist the dif-
ferent repair mechanisms via altering DNA structures [142]. However, prior
to and during tumorigenesis only small amount of mutations could have the
advantage of manifesting the ability to initiate or promote tumor growth.
Moreover, it became evident, that mutational spectrum of clonal tumor dif-
fers from type to another [88,160].
It is widely believed, that aggressive tumor has a heterogeneous mutational
profile, for it accumulates various mutations (Figure 2.3) that provide the
tumor with additional advances and phenotypes. For instance, size, cell-cell
interaction, invasive and metastatic ability, and therapy resistance. This
wide mutational profile takes a clonal shape, hence the term tumor sub-
colony. Some of these mutations are beneficial periodically, meaning that
they help tumor prognosis at definite time and might turn into passenger
mutations at later stages. While other mutations, are beneficial to the tumor
indefinitely. This mechanism is known to be Mutational Recurrence, i.e.
the important mutations start at early stage upon tumorigenesis and they
are pass on to the daughter cells. The Mutational Recurrence is a definition
that the majority of computational tools count on it.
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Whether the mutations occurred in early stages or were somatically acquired
during tumor-lifetime, the intra-tumor heterogeneity became sort of an indi-
cator for the tumor state.
More into The Concept of Recurrence
Likewise, the concept of Recurrence is also extended to address genes,
which are not only beneficial to cancer prognosis periodically, i.e. at partic-
ular stage. Generally, the genes which are positively selected genes during
cancer advances are termed Driver genes.
The identification of driver genes is also computationally challenging. In
Section 3.4, three different assays are introduced to detect driver genes from
different aspects. However, only tool Oncodrive-FM does not rely on the
concept of Recurrence.
More into Locus Heterogeneity
Heterogeneous locus means that both alleles exist. The existence of both
alleles indicates the possibility that both allele are going to be expressed,
whether in an even amount or not. The later is the most observed one,
however, the bias towards expressing one of them can be a result of various
reasons, both biological and technical [153].
When a gene in a heterogeneous site is expressed, identifying the tendency
towards expressing one specific allele can highlight the relevance of that allele
to the functionality of the gene. Particularly in cancer, identifying the specific
allele (Expression Specific Allele - ESA) could be an additional risk factor if
not a causative.
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3.1 The Cohort of RIBOLUTION Project
The cohort of RIBOLUTION project consists in total of 48 patients,
in which 40 samples are from tumor tissue (T), and 8 are control (BPH ).
The samples were divided into five subgroups [HIGH, MED, LOW, VLOW]
based on the following parameters: primary tumor, nearby lymph nodes, and
Gleason score, and the patients mortality was considered as well. Moreover,
only HIGH-group has paired tumor-free (Tf) tissue (see Table 3.1).
3.2 RNA Sequences
RNA sequences were obtained using TruSeq Technology from Illumina.
Before mapping the sequences to the genome, adapters were removed using
cutadapt [104] (See 8.1).
Afterwards, Segemehl was used to map the sequences to the reference genome
[64]. Reads were removed if, (1) they were mapped to multiple locations; (2)
their mates were mapped to different chromosomes.
Segemehl assigns the mapping score 255 to the uniquely mapped reads. Tech-
nically, high score means mapped to unknown regions and consequently such
reads will be excluded by variants callers. Therefore, the mapping quality
was then changed to 50 instead of 255.
Finally, the reads around exon-intron borders were re-aligned using testrealign;
a method embedded in Segemehl.
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3.2.1 Sequences Pre-Processing
Before calling the variants, reads were sifted to minimize false positive
discoveries. The following filters are encapsulated in Fig 4.3 (Step 1):
Known Repetitive Elements and Pseudogenes :
Repetitive Elements are identified on DNA level. Since there is no way
of telling, on RNA level, if the reads come from high coverage regions,
or if they come from repeated sequences, known repetitive sites were
removed.
Numts :
Numts (nuclear mitochondrial DNA seqments) in eucaryotic genome
are frequently observed to transport to the nucleus of the cell. The
causes for it vary between contamination, mutagenic agents, or even
stress conditions [76,87,150]. Therefore, sequences were as well checked
if they overlap nuclear mitochondrial sequences (Numts).
The annotated genomic regions were obtained from http://www.gencodegenes.
org/releases/19.html.
3.2.1.1 CDS Only-I
To keep coding parts only, reads overlapping the CDS intervals were kept
to the downstream analysis. Those bam files are the ones which have been
used to call variants.
The command intersect from bedtools/2.20.1 was used for this purpose
(more information in the Appendix 8).
3.3 Identification of Genomic Variations
The first step to work with variants is to select the correct set of bioin-
formatic tools for identifying them. The candidate tools, should fulfil the
requirements of the project aim to tolerate its restrictions.
3.3.1 Tools for Calling and Handling Mutations
In table 3.2 some of the widely used bioinformatic tools to identify vari-
ants are given. In contrast to methods used to identify SNPs and INDELs,
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the fundamental concept of cancerous variants methods is to compare tumor
sample with its matched normal sample. The ideal procedure is to take sam-
ple from the tumor tissue and tumor-free tissue, from the same individual.
This procedure enables the tools to detect tumor specific SNV s, by compar-
ing every locus containing candidate SNV s in matched samples [29,32]. This
requirement can not be filled within RIBOLUTION cohort, as the majority
of the patients have no matched normal samples.
Despite their advance approaches, heretofore almost every existing SNV call-
ing tool was developed to handle DNA sequences. As in section 2.2.1, the
differences between SNV s in RNA and SNV s in DNA were explained. Con-
sequently, these tools are not fit to be used with RIBOLUTION cohort.
Hence, the idea to implement a convenient pipeline became a must.
3.3.1.1 Samtools and Bcftools
Sequence Alignment/Map (SAM) is a format intended to flexibly store
large sequence alignments [94,95].
Samtools is a suit consists of different helpful utilities for shaping and em-
ploying the sequences, e.g. sorting, viewing sequences, fixing the reads mate
information, and calling variants.
The calling variants utility mpileup incorporates different parameters to
identify variants; for instance, number of reads covering the site, base quali-
ties and alignment mapping qualities.
However, Samtools and Bcftools together have serious restrictions. The
tools can not tolerate properly multi-allelic variants. Therefore, it takes the
most probable allele as the alternative one, instead of listing what exists in
the data. This could be a crucial obstruct when it comes to cancer samples.
Moreover, the likelihoods of multi-allelic INDELs are miss-computed this is
due to assuming the interdependency of the sites. This assumption does not
reflect actual data since sequencing and mapping are context depend.
The genotype likelihood `(g) is estimated through the following equation [93]:
`(g) = 1
mk
l∏
j=1
[(m− g)j + g(1− j)]
k∏
j=l+1
[(m− g)(1− j) + gj] (3.1)
where:
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k: number of reads
l: the first bases (l ≤ k) which align perfectly to the reference genome
j: the error probability of j-th read base
m: ploidy of the organism
In this study, Samtools/0.1.19 was used to call SNV s after reads were filtered
according to the best practice 3.3.2.
3.3.1.2 GATK
The genome analysis toolkit is one of the most popular tool to identify
and filter variants [109].
In principal, GATK was first intended to analyze exome and whole genomes
sequences produced by Illumina. Gradually developing its original purpose
to include RNA sequences analysing.
Moreover, besides human genome, GATK has evolved to tolerate other ploidy
organism, which is a huge advantage in comparison to Samtools. As the
observation report multiple allele in the site of cancer data.
The fundamental concept is to estimate for each base its genotype posterior
probability by considering the coverage of the base and sample expected
heterozygosity using the bayesian method:
P (G | D) = P (G)P (G | D)
P (D) (3.2)
where:
D: base content pileup
G: given genotype
P (D): probability of observing the base which is constant over all possible
genotype. Therefore, it could be ignored.
P (G): probability of observing the given genotype
In this study, GATK/3.4.0, and oracle-jdk8/1.8.0 51 were used.
3.3.2 Best Practice of Mutations/Variations Calling
The best practice of GATK overlaps in many steps with the recommended
practice of Samtools. Since the best practise provided and explained by
GATK changes now and again, therefore, it is necessary to provide the one
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which is used. The used practise in this work for calling variants pipeline
consists of the main following steps:
Polishing BAM Files :
After filtering the sequences in the previous steps, the status of the
reads were validated. Moreover,GATK expects specific information in
the header, such as adding group information, sorting the reads in
specific order (see Section 8.2) This was done using Picard [174].
Mark Duplicate Reads :
Depending on the complex and type of the library of the fragment to be
sequenced, sequencing could produce duplicate reads. The heart of the
matter is the disability of distinguishing between artefacts introduced
by the sequencer (e.g. PCR), or by a region being sequenced more than
once.
Removing duplicate reads is essential in most cases for number of rea-
sons; such as eliminating possible bias introduced by the sequencer.
Moreover, the constraints, parameters and measurements of the algo-
rithm in the majority of variants callers are assumed to have a certain
degree of independence. Duplicate reads, however, might disturb this
assumption and thus incorrect prediction. Duplicate reads were marked
using Picard [174].
INDELs :
INDELs are considered problematic zones to the sequence aligner and
can produce many artefacts. These artefacts can be mistaken as SNPs.
Therefore to increase variants calling sensitivity, local realignment around
INDELs is an essential step, for it reduces the number of mismatches
within the reads. Additionally, reads starts and ends are considered
more severely problematic if the INDELs occur there.
Quality score recalibration :
The tools in this package recalibrate base quality scores of sequencing-
by-synthesis reads in an aligned BAM file. After recalibration, the
quality scores in the QUAL field in each read in the output BAM are
more accurate in such that the reported quality score is closer to its
actual probability of mismatching the reference genome. The recalibra-
tion is not only done to the well-known base quality scores but also base
insertion and base deletion quality scores. These are per-base quanti-
ties which estimate the probability that the next base in the read was
mis-incorporated or mis-deleted (due to slippage, for example). These
probabilities enhance INDELs calling algorithm
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Variations identification :
The last step is to single out possible variants. In this step, only se-
quence mismatches with certain score are called (see Section 3.3.1.2
and Table 3.2).
The variants calling was performed by HaplotypeCaller.
3.3.3 Variants Annotating
As it has been shown in Section 2.2.1, variants could arise from different
resources. One way to size the search pool is to classify SBS based on the
change in the amino acid. Therefore, variants annotating is an essential
step to distinguish relevant variants from others and precisely to distinguish
synonymous from non-synonymous variants.
3.3.3.1 Variants Effect Predictor (VEP)
The tool variants effect predictor (VEP) predicts the potential effect of
given variants (SNP, SNV , INDEL) by looking into known transcripts. VEP
first searches its local and remotely installed databases for the given variant
structural position in the transcript. The different databases help to address
variants in coding and regulatory regions. When available, afterwards VEP
derives the appropriate form to each allele and compares it to the reference
genome (e.g. different codons if the variant falls within an exon) [110].
In this study, VEP v82 was used, with the following databases:
dbSNP version 144
ESP version 20141103
COSMIC version 71
ClinVar version 201507
gencode version GENCODE 19
genebuild version 2011-04
assembly version GRCh37.p13
HGMD-PUBLIC version 20152
3.3.3.2 SNPEff and SNPSift
SNPEff and SNPSift were mainly used to predict the effect of variants
exist in both tumor tissues and its matched tumor free tissues. In normal
situation, the observed allele in position i would be compared to the reference
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• initiator codon 
Figure 3.1: VEP and Consequence Types
Adapted figure from http://www.ensembl.org/info/genome/variation/
predicted_data.html#consequences, in which only variants with the indi-
cated effect are kept.
allele, e.g. Ai → Ti | A : ref, T : non.ref . However, in cancer case and in
the presence of normal tissue the interest would be the difference between
germline and cancerous mutation. Meaning that, if in tumor sample, the
variant in position i was Ai → Ti | A : ref, T : non.ref and in its matched
tumor free sample, the variant was Ai → Ci | A : ref, C : non.ref ; then the
valuable information would be the impact of Ci → Ti | C : tumor− free, T :
tumor [30, 31]. This path was followed only to HRP (see Section 4.1.6).
3.3.4 Functional Effect Prediction
Variants are more than genomic point alteration; this position could have
evolutionary meaning, making the alteration value highly appreciated. Table
3.3 highlights some of the current approaches to address this specific issue,
some of which were used in this study. This kind of prediction assists the
driver variants identification.
To have a flavour, SIFT and PPH2 were both used as input to Oncodrive-FM
tool (see Sections 3.3.4.1, 3.3.4.2, and 3.4.2 respectively).
3.3.4.1 Sorting Tolerant From Intolerant Algorithm (SIFT)
SIFT is a method designed to detect whether an amino acid change/sub-
stitution has an influence on the functionality of the protein [85,121].
As it has been formerly presented (Section 2.2.1), disease associated SNV s
have a different structural properties in comparison to silent SNV s. Thus
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the idea of using protein structural information to predict the after-effect of
SBS in amino acid came to light.
SIFT could estimates its predictions from sequence information directly. This
empowers the prediction to consider phylogenetic information as well. In
principle, if the algorithm was fed with raw sequences, SIFT aligns the input
to homologous sequence database. MSA of these homologous sequences, in-
cluding the input sequence, will expose the conserved positions. Conserved
positions indicates related functionality importance. The conservation pa-
rameter along with the harshness of the amino acid substitution make to-
gether the final score. In absence of MSA, similar physiochemical properties
of other amino acid will be considered instead within the prediction method.
The given score to SBS ranges between {0 . . . 1} | score < 0.5 are deleterious.
In this study, SIFT/5.2.2 was used.
3.3.4.2 Polymorphism Phenotyping v2 (PPH2)
Using Naive Bayes classifier PPH2 calculates the posterior probability
for the given variant, whether its effect is deleterious or not. Moreover, false
and true positive are estimated and reported too.
PPH2 prediction comes from multiple sequence alignment information (MSA)
and protein 3D structure. Selective properties and features were considered
from the former two parameters and fed to the probability classifier. For
example, CpG context, area surface accessibility, alignment depth, etc. Like-
wise, the given score ranges between {0 . . . 1} | score > 0.5 are deleterious
(the opposite to SIFT)..
Generally, PPH2 prediction can be cataloged into damaging, non-damaging,
probably-damaging, benign, and/or other sub-categories [3].
In this study, PPH2 (version 2.2.2) scores were obtained via VEP tool (see
Section 3.3.3.1).
3.4 Methods for Identification of Driver Genes
Given the set of cancerous mutations which are believed to contribute
to tumor progression, the current following approach is aimed to identify
potential genes which are responsible for Tumor development consequent to
these mutations.
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3.4.1 Oncodrive-CLUST
A novel method for measuring the bias of genes towards large muta-
tional clustering, through distinguishing between beneficial mutations and
passenger. The underlying assumption is that the accumulation of non-
synonymous mutations (cluster) is taken to be a marker for positive selec-
tion, since synonymous mutations are in principle under no selective pressure
(background) [159]. Once candidate clusters are found, each cluster will be
given a score (see Equetion 3.3), the gene is considered a potential driver
gene if the sum of all its clusters score contains was significant in comparison
to the background (entire set of genes).
Clusteringscore =
∑
i
fractionMutation
(
√
2)2
(3.3)
where:
i: protein positions within the cluster
fractionMutation: ratio of mutations falling in position i to the complete
mutations set
The version 1.0.0 was used in this study.
3.4.2 Oncodrive-FM
The second tool in Oncodrive suite is developed to estimate genes ten-
dency to accumulate mutations of high functional impact across several tu-
mor samples. Oncodrive-FM does not assume Mutational Recurrence as
underlying model, which gives it the advantage of detecting mutations with
low frequency (see Section 2.3.1).
The functional measure bias (FM bias) detects candidate cancer drivers based
on the mutations quality regardless of their recurrence. The main two steps
are, measuring the mutational functional impact of all genes across all given
tumor samples, then assessment of the measurement significance [53]. The
quantity/effect is given for each mutation in form of a score. The score is
obtained by other methods (see Table 3.2).
In this study, SIFT and PPH2 where used for scoring the mutations (see
Sections 3.3.4.1, 3.3.4.2) with Oncodrive-FM version 1.0.1.
33
Chapter 3. Materials and Methods
3.4.3 MutSigCV
Figure 3.2: The Concept of MutSigCV
Figure from https://www.broadinstitute.org/cancer/cga/mutsig, in
which MutSigCV strategy illusterated. The genes are indicated by coloured
bands, while red triangles represent the mutations. A, B, C, & D indicate
different tumor samples that their overall mutations are aggregated into one
tally. The score of each gene will be then computed as in Equation 3.4 and
accordingly the significance of the gene is determined.
MutSig stands for Mutations Significant. Originally, MutSig is a method
to analyse list of mutations in multiple Tumor samples, to identify potential
driver genes by establishing a mutational background. The candidate genes
will be the genes which were found more mutated by chance [120,146].
The original algorithm assumed a category-specific average mutational back-
ground (µ), so that to calculate the p-value for each gene, a score should be
first assigned to it. The gene score comes from binomial probability distri-
bution (see Equation 3.4).
In 2013, the method was then developed to more complex form, when [88]
MutSig matured into MutSigCV: Mutations Significant Covariates. Mut-
SigCV takes into account additional factors which define the molecular state
of each gene. These factors are genomic-based, for example: chromatin sta-
tus (closed, open), gene expression, and local GC content.
Moreover, the results reported by MutSigCV are influenced by patient-based
factors as well, such as, the type of SBS , or mutational rate (see Figure 3.2).
Similarly, the mutational background is a category-specific, i.e. by pool-
ing the mutations into categories. It is worth mentioning that INDELs are
counted as Null mutations.
Sg =
∑
c
−10× binomial(nc, Nc, µc) (3.4)
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where:
c: mutational category based on sequence context, or
functional impact.
Sg: score of each gene.
nc: number of mutations (n) in a category (c).
Nc: number of bases (N) covered by those mutations.
µc: background mutational rate for category (c).
MutSigCV 1.4 was used in this study. The reads were first counted using
the tool HTSeq [11] then, the gene expression was computed using the R
package from Bioconductor (see Section 3.6). In summary, estimating the
genes expression following the following steps:
• Counting reads
• Removing genes with low reads count (< 4) if its low count was ob-
served in at least 4 samples
• Estimate a normalization factor, library size and then normalize the
counts accordingly ( genes count
library size × normalization factor )
• Calculate the mean of the the log2 values in all samples gene-wise.
3.5 Computational Assays
In the following sections the fundamental computational methods will be
introduced, which they underline some of the major assays in this study or
helped deriving results and conclusions.
3.5.1 MATH Score
MATH, Mutation-Allele Tumor Heterogeneity, is a quantitative approach
intended to measure the intratumor heterogeneity [115,116].
First, mutant-allele fractions (AH ) is computed for every mutation as in
Equation 3.5. MATH is, then, the width of the distribution of AF to its
central (see Section 3.6). The assumption is, a heterogeneous tumor tends
to have a wider AH distribution in comparison to a homogeneous tumor.
A heterogeneous tumor conspires cells multi-colony, i.e. different cell pop-
ulations (see Section 2.3.1), and therefore, its AH distribution tends to be
centred around low allelic fraction.
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Figure 3.3: MATH Computation Assay
(a) The illustrated pipeline is applied. First, a cut-off is set, so that MATH
score will be computed to only genes passing that cut-off. The cut-off is
the number of SNV s to use for estimating the score. It is then computed
as in Equation 3.6. When MATH score is computed for the gene in each
patient, the heterogeneity level of the gene is estimated by combining the
scores from all patients (b). To draw a conclusion for the gene, the scores
variation between all patient is visualized via a boxplot (b.1). This type
of visualization helps highlighting the differences between the subgroups.
Individual observation per patient for the gene is directly visualized in a
heatmap (b.2). In the present study, both are used.
Let χ be a mutation site; besides the depth of ref-allele τ , n number of total
non-ref alleles which were detected {ω1 . . . ωi . . . ωn} | ω is number of reads
support each non-ref allele.
The total depth of this site would be: χdp =
∑n ωi + τ
The allele depth frequency is then defined to be:
AH =
∑
ωi
χdp
(3.5)
MATH = 100× MADAH
medianAH
(3.6)
In this study, MATH score was implemented using R, and was further used
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as an indicator, how heterogeneous the locus is, in which the gene of interest
was expressed.
3.5.2 Statistical Tests
The following sections introduce the main statistical tests, that were
used in this study.
3.5.2.1 Linear Regression
In statistic, describing the relationship between different variables could
be done using supervised learning. In particular, linear regression is consid-
ered the simplest form of predicting the quantitative response (Y) based on
one single predictor (X) (Equation 3.7).
Y ≈ β0 + β1X (3.7)
Together, β0 and β1 are the model coefficients, where:
β0: is the intercept, the value of Y when X = 0
β1: is the slope, the average increase in Y predicted by
one-unit increase in X
3.5.2.2 Kruskal-Wallis Test
A nonparametric test that it is used to test the association between one
nominal variable and one measurement variable. The main idea is to test
whether the mean ranks are the same in the tested variables. Since Kruskal-
Wallis test is a nonparametric test, it means that it does not assume that
the data is normally distributed, which would be usually tested with one-way
anova instead. Equation 3.8 defines the underlying statistics of the test.
H = 12
N(N + 1)
k∑
j=1
R2j
Nj
− 3(N + 1) (3.8)
where:
N : samples size N = N1 +N2 + · · ·+Nk
R: ranks of the data R1, R2, . . . , Rk
k: number of samples
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3.5.2.3 Exact Test of Success
The exact test of success could be measured using several statistical
tests depending on what values the data could have.
Some members of exact test family are: Exact Binomial Test, Fisher’s Exact
Test, and Chi-Square Statistic. Exact tests calculates exactly the significance
of the deviation from a null hypothesis, rather than entrusting approxima-
tion.
Exact Binomial Test :
If the aim was to test one variable with two possible values only, exact
binomial test is used (Equation 3.9). The H0 assumes that the two
possible values are equally likely to occur.
P (χ = i) = B(i|p, n) =
(
n
i
)
· pi(1− p)n−i (3.9)
where:
P (χ): probability of observing χ
i: number of success | i ≤ n
n: sample size.
as shown in [1].
Fisher’s Exact Test :
Another member of exact test family is the Fisher’s Exact Test, which
is used to compute the significance between success and failures. This
is it, exact binomial test takes the number of success in comparison to
the total number of trials. While Fisher’s exact test takes the number
of success and failure (Equation 3.10).
As given in [4], for a contingency 2× 2 table
P (t) = P (n11 = t) =
(
n1+
t
)(
n2+
n+1−1
)
(
n
n+1
) (3.10)
Which test and when it was used will be indicated along with the associated
procedure/data.
3.5.2.4 Test of proportions
Let N1, N2 be two random samples and P1, P2 are the proportions of
categorical characteristic, whether they differ significantly or not.
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The null hypothesis H0 assumes no difference between the two proportions
P1 = P2 and, therefore, the two samples N1, N2 were drawn from the same
population.
Under the assumption that the proportions are closely normally distributed,
its mean µ and standard deviation σ would be, as shown by [155], given by:
µP1−P2 = 0
σP1−P2 =
√
PQ( 1
N1
+ 1
N2
)
(3.11)
where:
Q = 1− P
P = N1P1 +N2P2
N1 +N2
To test against significant observation the estimated value would be, then,
given by:
z = P1 − P2 − 0
σP1−P2
= P1 − P2
σP1−P2
(3.12)
3.6 Others
A collection of other tools were used in this study, the vast majority
are widely used and known, e.g. Linux utilities, Perl and R, the following
sections highlights the less known tools, which mainly were used to visualize
the results:
R :
Besides the standard functions (mad, mean, sd, statistical tests, etc.),
the following packages were used as well:
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• GenVisR: A Bioconductor package that produces highly customiz-
able quality graphics for genomic data.
• TrackViewer: A Bioconductor package that was designed to gen-
erate elegant tracks or lollipop plot out of NGS [74].
• pheatmap: A CRAN package to implement and control heatmaps.
• NMF : A CRAN package of the Algorithms and Framework for
Nonnegative Matrix Factorization. Along with pheatmap package
used to generate heatmaps plots.
• biomaRt: A Bioconductor package that provides an interface to
BioMart databases.
• edgeR: A Bioconductor package that performs empirical analysis
of digital gene expression data. Used functions are: cpm, DGE-
List, calcNormFactors
• clusterProfiler: A Bioconductor package that analyses and
visualizes statistically the functional profiles for genes and gene
clusters.
Others :
From cbioportal [24, 49]:
• Mutation Mapper: Generates lollipop plots on protein level by
supporting the genomic coordinates, annotated variants, and pro-
tein domains (a 3D structure view possible if available).
• OncoPrinter: A simple representation to the clinical annotation
tracks.
From UCSC browser:
• LiftOver: Lift Genome Annotations, used to convert GWAS list
from GRCh38.p2 to GRCh37/hg19.
From GWAS Catalog [171]:
The NHGRI-EBI Catalog of published genome-wide association stud-
ies.
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Figure 4.1: The RIBOLUTION cohort and its main subgroups.
The cohort consists of 40 patients with positively PCa diagnosis. Samples
from prostate tissue were obtained and classified into subgroups. The ag-
gressive level of the cancer was determined by Gleason score and lymphnodes
metastasis and therefore the subgroups were called: very low risk (VLOW ),
low risk (LOW ), medium risk (MED), & high risk (HIGH/HRP). Addition-
ally, 8 positive BPH samples are considered the control (CNTRL). (a) The
subgroups are shown, where numbers in the lower right corner are the num-
ber of patients in each subgroup. HRP were the only patients that tumor
free samples (Tfree) from the same prostatic tissue is taken along with the
tumor. Therefore, a sub pipeline for these patients is contemplated (shown
in (b)). The classification and its related clinical data could be seen in Table
3.1, for quick access check the glossary 9.
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All samples were whole transcriptome sequenced, ak.a RNA-sequenced. Re-
stricting the analysis to the coding parts of the regions could address the
potential influence of genetic alterations on/with PCa, as the functionality
of the genomic coding parts (CDS) are comprehensively explored. This con-
siderably extensive knowledge aids our search to potentially cancer related
SNV s and genes. Therefore, in the downstream analysis, sequences in in
CDS regions were selected (known as CDS Only I filter), and the effect of
SNV s on the protein product subsequently is considered (known as CDS
Only II filter).
The results were sorted as follow:
1. Methods establishment, first and foremost the variant calling pipeline,
(CVR Module).
2. Obtaining valid variants, then according to public databases will be
entitled.
3. Identification of candidate genes, then related advance analysis is run.
The downstream analysis is visualized in Figure 4.2
4.1 Calling Variants in RNA-Seq (CVR Mod-
ule)
The CVR Module was designed to embrace RNA-sequences up to iden-
tify candidate variants. Figure 4.3 visualizes the major six steps in CVR
Module. Each of which consists of multiple sub-steps (not shown).
Next, the major six steps are given in details:
4.1.1 Step 1: Reads Filtering
The first novel thing in the CVR Module is that it starts with reads filtering,
where among other criteria, Numts regions were filtered out (see Sections
3.2.1 and 8.2). We believe that this is the first study in which controlling for
Numts before variants calling has ever been done.
Reads overlapping known repeats were also filtered out, as it is by definition
contradicts with RNA-Seq. Filtering, reads harbouring CDS regions were
the ones kept for the further downstream analysis (CDS Only - I).
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Figure 4.2: An illustration of the downstream analysis of this study.
The terms Mutations & Variants are used interchangeably. Starting with es-
tablishing mutations identification methods, followed by understanding their
role in their local regions. Subsequently, potential PCa associated genes were
identified via functional mutations.
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Figure 4.3: The CVR Module (Calling Variants in RNA-Seq).
Down to Step 5 the different steps were applied to the whole cohort for it
does not require matched tumor free samples. Step 6 is an optional step; it
was applied in case of available matched normal samples (to subgroup HRP
only). Focusing on the genomic coding parts, in Step 1 reads overlapping
known repeats, Numts, and pseudogenes regions were filtered out. In Step 2
the best practice of each tool was applied. In Step 3, only variants identified
by both tools were kept (termed as Reliable Mutations). Mapping tools can
stumble when true SNV s occur towards reads end. Therefore, to avoid any
artefacts, in Step 4, the variants were filtered according to their position on
the read in (a), and on the genomic annotation (b), while in (c) the variants
length filter was applied, so that INDELs were removed if they were of a size
larger than certain proportion to the reads size. Shown: ×: failed due to its
position at the end of the reads in the entire pile. ?: depending on the chosen
cut-off, SNV s at this position might be removed or kept.
√
: a passed SNV .
Finally, Step 5 Quality and depth were chosen based on the distribution of
these parameters in the data. The quality refers to the score given to the
confidence of SNV s calling. Number of reads covering the site of SNV s is
termed as depth, this criterion helps eliminate SNV s with scanty signal.
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4.1.2 Step 2: Mutations Calling
Samtools and GATK are both SNVs callers with several differences in their
underlying algorithms. As previously explained in Section 3.3.2, the best
practice of two tools was used. Particularly, the RNA-seq friendly practice
proposed by GATK was the one applied.
4.1.3 Step 3: Joined Calls Only
Due to the combination of different parameters that each tool applies, differ-
ent sets of called mutations are usually reported. Therefore, only mutations
identified by both tools are trusted by first hand. This procedure has re-
sulted in keeping more than 50% of SNVs that were called by GATK and
almost 21% of SNV s that were called by Samtools. The amount of initially
called SNV s from both tools and the set that actually has been used in the
downstream analysis is illustrated in Figure 4.4. The remaining SNV s have
a better calling quality and higher depth as it is shown in Step 3 in Figures
4.6, and 4.5.
Figure 4.4: CVR.Steps 2-3: First SNV s Calling.
The amount of SNV s which were called by tools Samtools and GATK . The
overlap represents the amount of SNV s that both tools jointly called and
those typically were used in the downstream analysis. The variants calling
by each tool was done with one single filter: Minimum base quality a cut-off
for a base to be considered; a SNV with calling quality less than 10 will be
dropped, as the chance of making a false call is equal to 0.1.
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4.1.4 Step 4: Dubious Loci and INDELs
After filtering the reads in the first step, the reads were transformed into
intervals, i.e. the edges position of the reads (the 5’ and 3’) extended by
number of bases n = 10 in both directions (see step 4 in Figure 4.3 [a-b]).
That is, every read is presented by two entries in the bed files, i.e. the 5’
window and the 3’ window (W5,W3). In this fashion, it was plausible to
compare detected SNV s with their position on the reads.
Let i be a genomic position where a possible SNV was detected. The total
number of reads covering i is referred to by DPi. Every variant (SNVi) was
given a score (Equation 4.1), which in return determines the proportion of the
variants position to the reads edges, if i falls in any of the windows (W5,W3).
Scorei =
Σ(DP iW5 , DP iW3)
DPi
(4.1)
Then a cut-off α is checked for the filtering. From the data (not shown), the
chosen α = 0.5.
Muti =
Keep Scorei ≥ αRemove Scorei < α
This filter is illustrated in step 4.a of Figure 4.3. The sketch shows three
different cases, a fail case (×) because the position of the detected SNV is at
the end of the majority of its reads. Reads edges have a particular source of
error especially in variants study, because the adapters in some reads might
have not been properly and entirely removed (see Section 8.2.4 for further
details and observed cases). The second case is a passed SNV (
√
), while the
third case depends on the chosen α for the position of the SNV in some reads
is towards the edges and in some other reads towards the middle (?). Figure
4.5 shows the effect of each filter to finally obtain the minimum number of
false calls.
The results of applying these filters are shown in Figure 4.5. In step 4.a of
Figure 4.3, 10bp is the size of the window, and α = 0.5 is the chosen cut-off
to exclude variants.
The same strategy was applied to exclude variants on the edges of the an-
notations. This filter was applied to overcome two problems: 1) reads miss
mapping by sequence aligner, and 2) the incapability of distinguishing be-
tween the lack of coverage and a deletion. Both reasons result in false positive
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INDELs (Step 4.b in Figure 4.5).
Since ORF are the annotation of interest, the edges of CDS could be the
splice sequence, therefore the left and right windows had to be smaller (n = 2)
to allow potential splice variants passing the filter.
It is worth mentioning that the given score is not necessarily smaller than 1
(up to ∞). This is due to the fact that the depth reported by the variants
callers is not the coverage of the site. That is, variants callers apply first
internal quality filters then count the depth of the site by only reads passing
these filters. Therefore, reported depth is usually smaller than the actual
coverage. In summary, scores which were > 1 were at most 1% of the entire
observed scores.
The final filter in this step is the INDELs filter, in which a control over IN-
DELs length is applied (Step 4.c in Figure 4.5). This filter has approximately
the same intention of the previous ones, additionally, it came to our notice,
that variants callers could mistaken the mix of overlapped reads ends and
lack of coverage as potential INDELs. Figure 8.2 is a perfect example of this
case (see Section 8.2.4). As Equation 4.2 states, every identified INDELs
(| INDEL |> 1) is given a score where its length divided by the length of
the read (| Read | = 100), the chosen α = 0.7. We believe, this is another
novel procedure in context of SNV s calling in RNA-seq data.
Scorei =
| INDELi |
| Read | (4.2)
INDELi =
Remove Scorei ≥ αKeep Scorei < α
The lines in Figure 4.5 are intended to show the progress of these filters.
However, they do not show how these three filters (4.a, 4.b & f.c) contribute
to improve detected variants, since the affected variants are less than 1%.
4.1.5 Step 5: Quality and Depth
Quality and depth are the most important filters, since they decrease sig-
nificantly the false called sites. In concept, sites with high depth (reads
coverage) tend to report trustful estimations and predictions, i.e. more reads
help sharpen SNV detection and assist estimating precise quality. Since es-
timating the calling quality depends on many parameters such as mapping
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Table 4.1: Summary of identified SNV s.Basic summary of identified SNV s
after removing dubious loci. Observed quality and depth after the last filter
in Step 4 (c).
Depth
Min 1st Qu. Median Mean 3rd Qu. Max
1 7 19 40.84 45 6054
Quality
10.01 83.77 266.80 750.80 771.80 132700
quality, large coverage strengthen the computation.
To determine most suitable cut-off the statistical summary of each param-
eter was checked, and accordingly the cut-offs were, DP = 20, QUAL = 150
(Table 4.1). Together, these relatively high cut-offs increased the general
characteristics of the SNV s.
4.1.5.1 CDS Only - II
The variants effect is usually related to the gene they exist in. For instance,
a variant that exists prior or posterior the gene does not have an impact on
the final protein product (V ar1 in Table 2.2). The positive influence of this
filter on the final set can easily be seen in Figure 4.5.
4.1.6 Step 6: Available Matched Normal
This step is applied only to the HRP group, for only those have available
matched normal tissue (see Table 3.1). This step can not be seen in Figure
4.5, but the results are summarized in Table 7.1.
We refer to the set of variants found in both samples as ”Shared”, while what
remains independently in each sample as ”Tumor-Only” and ”Tfree-Only”.
Since the rest of the cohort do not have matched normal tissue, specificity
in terminology for each group was not required.
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Figure 4.5: Effect of CVR Module on the SNV s.
The lines display step-wise improvement of applying CVR Module. The
consequences of applying these filters were chosen to be shown on SNV s and
INDELs. The effect was then split into plots (4.5 & 4.6). Clearly, the amount
of SNV s in HRP (HIGH-Tumor , HIGH-Tfree) is higher than the rest of the
cohort (squares and triangles), due to the samples number. The first step
in filtering, on reads level, can not be seen here (SNV s calling was not yet
done). In case of Depth and Quality, the jitter points represent the median
absolute deviation computed with mad from R while the amount is given by
the raw value. Y-axis in the plot INDELs Amount is the ratio of observed
amount of INDELs, defined by ]INDELs(]INDELs+]SNV s) .
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4.1.7 Excluding INDELs
Despite the specific filtering, from technical perspective, INDELs constitute
a special problem. We have seen many cases were false INDELs escaped the
filters. Various reasons stand behind falsely detected INDELs, which were
in most cases distinctive ones (see Section 8.2.4).
Some of the main reasons: filters and tests are designed to fail so that pos-
itive calls can pass it. Additionally, the false INDELs were provoked by the
variants callers or sometimes the whole region has a low mapping quality,
which make it harder for variants callers to make the right call (see Figure
8.3). For these reasons INDELs were eliminated from the final analysis.
Figure 4.6: Effect of CVR Module on the SNV s quality.
Step-wise improvement of applying CVR Module on the Pherd Quality Score
(y-axis) of the SNV s and INDELs. Pherd Quality Score is the calling confi-
dence, it is logarithmically related to the base-calling error probabilities, i.e.
the higher the value is the very unlikely the calling was false.
4.1.8 The Concept of SNV Uniqueness
Another important concept regarding mutational scaling is uniqueness.
Rephrasing it, a gene can have multiple transcripts, therefore, the muta-
tion on each transcript can have a similar, different, lower or higher effect in
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comparison to itself on other transcript (see Table 4.2).
In this study, there were mainly two different definitions to SNV Uniqueness:
4.1.8.1 Genomic Uniqueness
The genomic uniqueness is when the SNV is defined by its genomic position
neglecting all other parameters (sample, gene, etc. ). The SNV is then
represented by chr, pos where chr and pos are the SNV position on the
chromosome.
This definition is particularly helpful, when the questions regarding quality
and novelty are asked. The redundancy of the SNV in this case is not
beneficial.
4.1.8.2 Transcriptomic Uniqueness
On th other hand, the transcriptomic represents the different forms a SNV
can take. That is, the genomic uniqueness indicates the existence of a SNV ,
while the transcriptomic uniqueness indicates the effect of a SNV (see Table
4.2).
Therefore, a SNV is considered unique, if it did not share all the following
information with any other SNV :
• Patient ID
• Gene and transcript ID
• DNA position, cDNA position,and AA + Protein Position
• Final effect (upstream, nonsense, etc.)
Moreover, even within one patient some SNV s might have more than one
non.Ref allele (most frequent in INDELs). In this case all different forms are
also considered.
This definition is used when the full mutational effect status of the gene is of
interest; in this case all isoforms are needed instead of taking only one effect.
4.1.8.3 Protein Only
Additionally, as in Table 4.2, some SNV s do not exist within the body of the
transcript, for instance the upstream variant; this filter is also termed as CDS
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Only - III. Those SNV s do not have a direct influence on the protein level.
Technically, the reads in RIBOLUTION were not mapped to transcript-
reference; the fundamental concept is mapping the reads to genomic locus
without specification. Therefore, an upstream, downstream or splice variant
can not be clearly addressed since there is no proof that their particular
transcript was the one expressed or not and because of them a phenotype
resulted. To end up with valid provable results, SNV s with such effect types
were excluded from the downstream analysis (see Figure 3.1 in Section 3.3.3.1
for the effect considered in this study).
The distribution of SNV s per chromosome is given in supplementary Section
7.1 for every subgroup (Figure 7.1 & 7.2). The position of the SNV s in the
protein is also given per subgroups in Figure 7.3 & 7.4.
Table 4.2: Five different cases to one variant taken from HIGH-Tumor .
Although the variant might occur in one patient, still it could have mul-
tiple facets. The variant is a known SNP with ID rs9153 and its exact
genomic position is chr22:24108412. This SNP was found in one patient
(P497410), and it occurred in multiple transcripts from three genes which
are in the range of each other in that genomic locus. According to the
tool VEP (Variants Effect Predictor), in total, 13 transcripts which were
effected by this SNP, only five cases were shown here for conveying the
idea. Each case represents the individual consequence on the transcript.
For the first two transcripts the SNP is located outside therefore, it has
no position the final protein (indicated by ”-”), these two cases were later
removed (see Section 4.2.2 for further details).
Gene Transcript cDNAPosition
AA +
Protein
Position
Impact
ENSG-99953 ENST-489582 -/593 - Upstream
ENSG-169314 ENST-305199 -/681 - Downstream
ENSG-250479
ENST-484558 881/1171 Y104Y Synonymous
ENST-517886 305/494 R87* Stop gained
ENST-520222 94/384 T31M Missense
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4.2 Variants Validation
Even with the presence of DNA samples, false positive calls are hard to de-
tect. Therefore, the classical approach is to check how many variants were
found in public databases.
The SNVs were then categorised by the degree of confidant detection: First
if the SNV was reported in dbSNP, COSMIC, or both. Then, if the SNV
was reported in GWAS catalogue as PCa associated variant (PCAV ). After-
wards, the SNV was also checked if it was reported in at least one study, or
in other ”upcoming” public database (e.g. clinVar).
Group1 ... Groupm 
𝑅𝑎𝑡𝑖𝑜𝐺𝑟𝑜𝑢𝑝 =
𝐾𝑛𝑜𝑤𝑛 𝑆𝑁𝑉𝑠
𝑇𝑜𝑡𝑎𝑙 𝑆𝑁𝑉𝑠
  
Groupi Groupm 
dbSNP COSM PCAV Pub Novel 
SNV1 
(chr,pos) 
1 0 0 0 0 
... 0 1 0 1 0 
SNVn 
(chr,pos) 
0 0 0 0 1 
Figure 4.7: The scheme of validating the SNV s final set.
The sketch elaborates the scoring scheme of checking, whether the variant
was found in at least one additional resource other than RIBOLUTION co-
hort. The header row of the table represents the tested criteria: dbSNP,
COSMIC, PCAV (PCa Associated Variants), Pub (any additional publica-
tion or data base) & Novel (not found in any of the previous criteria ). Found
SNV s (known) pile up according to each criteria and are categorized by the
subgroup in the cohort; their ratio is then computed over the whole set of
the group. In case of SNV was found in all resources it will still be counted
as one for the group. Otherwise it is a Novel one.
Typically, for each criteria (dbSNP, COSMIC, GWAS , Publications + other
databases) a binary value is given:
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Criteriai =
1 found0 notfound
Finally, the ratio of each criteria is computed as in Figure 4.7 to show the
degree of detection fraction in each subgroup in RIBOLUTION cohort. This
ratio is computed group-wise for every criteria (see Figure 4.8).
Figure 4.8: Detected SNV s classified by the criteria.
The estimated ratio of found SNV s in different resources vs. novel ones, i.e.
SNV s that were found only in this cohort. Y-axis displays the ratio of SNV s
found by the resource. The ratio is defined by SNV s number divided by total
number of SNV s in each subgroup. The term novel was given to any SNV
that was not found in other resources (public data bases or publications).
At this point, what matters most is validating the SNV not its quantitative
presence. Therefore, for each group (VLOW, LOW, etc.), the SNV is repre-
sented by its position on the chromosome (chr, pos). Thus when the SNV by
this definition, is found in multiple patients it will be considered only once.
Interestingly, despite the high identification score in dbSNP, only 3 SNV s
were found in GWAS catalogue, and, those three were found in different
patients in every group (see Table 4.3).
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Table 4.3: Known PCa associated SNV s which were found in the cohort.
: SNV was identified by dbSNP and COSMIC. F: SNV was identified
by dbSNP and publication. The cells contain the number of patients in
RIBOLUTION cohort having that mutation. The column Σ shows the total
number of patients having that particular SNV .
Chr Pos C V L M HIGH ΣShrd T-Only Tf-Only
2  238443226 2/8 5/8 1/8 3/8 1/16 1/16 1/16 14/64
10  100147060 1/8 1/8 1/8 0/8 1/16 1/16 1/16 6/64
19 F 51361757 1/8 0/8 1/8 2/8 2/16 0/16 0/16 6/64
From Table 4.4 a clear observation could be concluded. The amount of novel
variants does not exceed 15% of the total detected SNV s. Additionally,
its quality is as good as the rest known SNV s if not better in most cases.
Therefore, we believe, Novel SNV s appear mostly to be true positive, and
therefore they were kept in the downstream analysis.
4.2.1 Known and Novel SNVs
As it has been seen in Figure 4.8 the set tumor-Only in HRP tends to
have the lowest ratio of SNV s found in dbSNP (0.82), and the highest ratio
of Novel SNV s (0.17) followed by tfree-Only (0.15). This difference was
tested using the Test of proportions and was stated to be significant (p-value
= < 0.05). Then the difference in ratio of SNV s found in dbSNP between
these two sets was also checked using the same test. This difference has also
been proven to be significant (p-value = < 0.05).
This observation signifies the concept behind the SMT (Somatic Mutation
Theory), a hypothesis that originated in 1914 with chromosome defect and
then evolved through the years sparking many known concepts in between,
such as 1-hit mutation, 2-hit mutation, and driver vs. passenger mutations.
The basic idea is that genetic alteration could progress to form cancer if the
microenvironment was in abnormal state too (e.g. in case of inflammation).
Therefore, accumulating novel SNV s in tumor tissue fits logically.
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Table 4.4: Quick summary to the final SNV s set. The results were
split by the cohort subgroups, keeping in mind that the numbers
might not add up in case of HRP (High.Tumor 6= Σ(High.Tumor −
Only,High.Shared)), as applying the filter CDS Only-II was indepen-
dently done to each set.
Control (16890)
dbSNP COSMIC PCAV Pubs Novel
] SNV s 14931 6949 3 2411 1693
Median Quality 722.03 676.07 192.75 1199.42 1453.69
VLOW (15888)
] SNV s 14233 6931 2 2082 1399
Median Quality 760.57 705.71 209.79 1282.45 1573.04
LOW (15902)
] SNV s 14403 7036 3 1920 1246
Median Quality 776.88 713.13 722.03 1378.08 1682.01
MED (16244)
] SNV s 14427 6958 2 2218 1552
Median Quality 779.8 729.44 550.05 1272.07 1510.76
High.Tumor (22772)
] SNV s 19896 9014 3 3509 2543
Median Quality 760.57 711.65 865.48 1268.36 1482.6
High.Tfree (22355)
] SNV s 19583 8734 3 3407 2462
Median Quality 720.54 684.96 144.55 1148.27 1350.65
High.Tumor-Only (12653)
] SNV s 10511 5107 2 2530 1959
Median Quality 330.62 296.52 92.66 555.98 621.95
High.Tfree-Only (13146)
] SNV s 11105 5326 2 2465 1857
Median Quality 333.59 312.09 69.69 366.2 376.58
High.Shared (15570)
] SNV s 14348 6669 3 1686 990
Median Quality 906.61 866.58 1802.28 1564.14 1770.97
56
Chapter 4. Results
4.2.2 SNVs Annotation
After validating the final set of SNV s, predicting the effect of every SNV
within its local sequence is known as SNV s annotating. Learning the impact
of SNV s in its local region aids exploring their potential influence on the
final genes function. Most importantly, the effect of the SNV on the gene’s
product, the protein, is the main evidence and classifier, whether the SNV
is silent or non-silent. This information is a crucial parameter in detecting
potential driver genes or cancer associated genes.
To that end, the SNV s were filtered according to their effect on the protein.
Figure 4.9 shows the remaining effects after removing INDELs and removing
every SNV without protein effect.
We also observe, that in Tumor-Only the amount of non silent SNV s is
slightly higher than silent ones in Tfree-Only. This difference has been proven
to be significant. The effects of non silent SNV s with significant difference
are: missense, stop gained, stop lost, NMD transcript variants. Yet the silent
SNV s in Tfree-Only are significantly more in comparison to Tumor-Only.
Along with having more novel SNV s (as in Section 4.2.1), make the results
more agreeable. In Section 4.2.3 the observation becomes more evident when
novel SNV s in particular tend to be more non silent (missense).
Figure 4.9: Local effect of the SNV s within their sequence.
After removing INDELs and keeping SNV s of protein effect, the final list of
major consequence consists of 10 different effects (see Table 8.2 for full effect
description). The y-axis is the ratio of number of mutations having that effect
over the entire set of mutations. As the ratio of the remaining consequences
is very small, for visualization purpose the data were transformed into the
square root of the y-axis.
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4.2.3 Association With Clinical Parameters
The PCa is known to be associated with age, GS, PSA, and so is the capa-
bility of attaining additional SNV s. As a sort of validation, it is important
to check: whether the data provide the evidence of such association. If an
association exists, it would be followed by addressing its type and strength.
The association was measured for the whole Tumor samples in the cohort in
neglect of the given sub-grouping [HIFGH-T, MED, LOW, VLOW].
The tested mutational aspects for each patient are:
• AH: the median of allelic heterogeneity distribution, i.e. the median of
observed mutations in all Tumor samples.
• Mutations: absolute number of SNV s each patient possesses.
• Novel: SNV s that were found only in our cohort.
• Novel.Missense: the total number of novel SNV s found in the patients
with the effect missense.
The association was tested using linear regression (see Section 3.5.2),
where the question was if any of the clinical data may be used to predict the
mutational state, as in Table 4.5, or if any of the clinical data can predict
the allelic heterogeneity state of the patient.
Figure 4.10 visualizes three main concepts, the correlation between these
parameters using Pearson’s correlation (upper panel). The diagonal panel
visualizes the histogram of each parameter. The lower panel displays the
pair-wise scatter plot and its fitting line.
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Table 4.5: Predicting SNV s amount and its AH from clinical data. Re-
sults of regressing (predicting) the size of mutations on different clinical
factors: (1) GS: Gleason score [1,9], PSA: Prostate specific androgen,
AH: mutational allelic fraction [0,1]. Codes of significance: ‘***’ 0.001,
‘**’ 0.01, ‘*’ 0.05. As expected, in Tumor samples the more the patient
accumulates mutations the more novel they are.
log(Mutations)∼ Estimate Std.Error t.value P-value
Intercept 11.22395 0.4226 26.559 < 2e− 16 ***
Age 0.0004 0.0029 0.135 0.893643
AH -2.8118 0.6582 -4.272 0.000147 ***
GS 0.03759 0.0166 2.269 0.029715 *
Novel.Missense 0.0006 0.0002 3.915 0.000413 ***
PSA 0.0004 0.0006 0.658 0.514961
log(AH)∼
Intercept -4.19e-01 6.702e-02 -6.25 4.07e-07 ***
Age -2.53e-04 8.960e-04 -0.28 0.779390
GS 1.74e-02 4.595e-03 3.79 0.000589 ***
Mutations -9.38e-06 2.154e-06 -4.36 0.000116 ***
Novel.Missense 2.26e-04 4.442e-05 5.1 1.29e-05 ***
PSA 5.63e-04 1.434e-04 3.93 0.000398 ***
Several observations could be summarized from the figure. For instance, only
AH > 0.5 was mainly noticed in Tumor samples, i.e. the none-ref allele is
more present than ref allele. This realization could imply the expression
status of each allele. Specially, allelic expression fluctuation has been ob-
served [153].
Since the patients of RIBOLUTION Cohort fall in the same age category,
an association with clinical data is not observed.
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Figure 4.10: The correlation between different parameters in the Tumor sam-
ples.
Upper panel: results of Pearson’s correlation (r ∈ [−1, 1]). In the diagonal
panel: the histogram of the different parameters for the merged sub-groups
(HIGH-Tumor , MED, LOW, and VLOW). The lower panel shows the actual
data and their smoothing line. In total, 40 patients were tested for the corre-
lation using cor function and method ”Pearson”. GS: Gleason score, PSA:
Prostate Specific Androgen, AH : Allelic Heterogeneity, Novel.Missense:
SNV s found only in this study with missense effect.
The same association with SNV s in Tumor-Only was verified in Section 4.5.2.
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4.2.4 RIBOLUTION and ICGC
ICGC project is considered one of the most studied cohorts in cancer com-
munity. Therefore, it would be of great interest to check to what extent the
results of RIBOLUTION cohort are comparable to the PCa cohort in ICGC.
The ICGC project consists of 4 different populations: DE, UK, US & CA.
The DE and the UK were the appropriate populations to compare since they
are all Europeans.
(a) Mutated Genes (b) Identified SNVs
Figure 4.11: RIBOLUTION vs. ICGC-European cohorts.
Focusing on Tumor samples in RIBOLUTION cohort (the 40 Tumor sam-
ples) a comparison with the German cohort (DE: 11 patients) and the UK
cohort (UK: 108 Patients) in ICGC project was done via: (a) Mutated Genes
in RIBOLUTION cohort vs. ICGC project (b) Final set of identified SNV s
after restricting the set to include only genomically unique ones (as explained
in Section 4.1.8). In (b), the 6 shared SNV s with ICGC-DE were reported by
multiple studies in COSMIC; the 4 shared SNV s with ICGC-UK are known
SNPs but none was found in COSMIC or other disease associated studies.
As the number of patients differs dramatically, the intersection between the
3 sets was merely countable (ICGC-SNV s according to Dec.2015).
The comparison was first conducted on gene basis, where observed mutated
genes were matched with those mutated in ICGC. Then, another compari-
son on SNV s basis was carried out (Figure 4.11). Interestingly, only 6 SNV s
from between the German cohort of ICGC were found in RIBOLUTION ,
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these are: rs1063243 (chr7: 91726927), rs7102584 (chr11: 128782012),
rs935240 (chr12: 105568176), rs1042719 (chr5: 148207447), rs10828663
(chr10: 24813454), and finally a SNV which was repeatedly reported only in
COSMIC, namely COSM3755462, COSM3716477, COSM3755463, COSM3716478
(chr17: 3844787). It is worth pointing out, that rest 5 SNV s were also repeat-
edly reported in COSMIC. The genes were these SNV s occur are: AKAP9,
KCNJ5, APPL2, ADRB2, KIAA1217, and ATP2A3.
In the UK cohort four known SNPs were found: rs1727 (chr 10: 91066769),
rs376299731 (chr 1: 144828707), rs200522655 (chr 19: 53391420), rs35416438
(chr 15: 94910954). The genes are: IFIT2, NBPF9, ZNF320, MCTP2.
Clearly, none of them are among top candidate genes. Most importantly,
all found SNV s were in VLOW and MED subgroups of RIBOLUTION , i.e.
6 patients in VLOW and one patient in MED.
4.3 Identification of Candidate Genes
The identification of candidate genes which are most likely Tumor spe-
cific was firstly done with assessment of three different tools (see Section
3.4). The assay which was first followed, was to merge all Tumor samples
vs available control and Tfree samples (Tumor: 40 samples, vs., non.Tumor:
24 samples respectively). This assay was applied twice: first, under strict
conditions, i.e. only considering genes that were mutated in all patients.
This scheme excluded any other gene from the analysis even if one patient
from the entire set did not have the gene mutated. Second, the genes were
considered if they were mutated in at least 50% of the patients (see Figures
4.12 & 4.13).
These two assays were done in neglect of the difference in sample size, since
the two categories, Tumor and non tumor, were given independently to each
tool.The results of this approach were used to understand the Tumor-specific
genes.
The second assay, in which, each group was independently analysed to detect
driver genes, is used to understand the differences between cohort sub-groups,
and to highlight the results of the first approach.
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Figure 4.12: Illustration of sorting genes by patients number.
The simplified example shows five patients with list of genes {I, ..,4}. The
genes were sorted by the number of patients. At this point, mutations quan-
tity in the patient does not influence the selection. The highest rank a gene
in Tumor set can have is 40, the maximum number of patients, while the
rank of the gene in the non.Tumor can reach 24 at most.
Gene I √ √ × √ √ 
Gene II × √ × × √ 
Gene III × √ √ √ √ 
... 
Gene Δ √ √ √ √ √ 
Gene Δ 5 
Gene I 4 
G ne III 4 
Gene II 2 
... 
Entire Cohort 
Subgroups 
All Samples 
G1 
>= 50% Samples 
G
1 2
  
Candidate Genes 
All Mutated 
Genes 
>= 50% Samples 
G
1 2
  
Candidate Genes 
Identification 
Genes 
Ranking Using Different Methods 
One group 
at a time 
Figure 4.13: The concept behind candidate genes selection.
Genes were first ranked as depicted in Figure 4.12. After using different
methods to identify candidate genes, the nominated genes were then classified
into G1, the set of identified genes which were mutated in all patients of the
cohort (Tumor = 40, non.Tumor =24), and G 1
2
, the set of identified genes
which were they mutated in at least 50% patients of the cohort (Tumor >
20, non.Tumor > 12). Obviously, G1 is a subset of G 1
2
. Same strategy is
followed once with the entire cohort (solid line), and other with subgroup,
each one a time (dashed line).
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4.3.1 Entire Cohort and HRP
(a) Entire Cohort (b) HRP
Figure 4.14: Identification of Candidate Genes.
The pipeline behind identifying potential driver genes in the entire cohort and
in the subgroup HRP. The core idea is to combine the results of different
bioinformatic aspects to increase the detection specificity. The analysis was
done independently to the entire cohort, and to the HRP.
Right: the pipeline was applied twice, once before removing shared SNV s
and second after removing them. This was particularly done to evaluate
the outcome of SNV s found solely in Tumor tissue and those found in both
tissues. The analysed sets contained 16 patients, 16 Tumor and 16 Tfree.
Left: the main two categories are: Tumor samples vs. non.Tumor samples.
In the figure, HIGH-T is the Tumor samples in HRP (16 samples), HIGH-Tf
is the Tumor-free (Tfree) samples in the same sub-group. In total, Tumor
category contains 40 samples and non Tumor category contains 24. Since
the sets were analysed independently, the difference in the sample size should
not influence the fairness of the analysis. The bioinformatic aspects define
candidate genes by their spatial clustering ”tool Oncodrive-CLUSTER”, by
their functional impact ”tool Oncodrive-FM”, and by defining the molecular
state of the gene ”MutSigCV” (see Section 3.4). After defining the list of
candidate genes by filtering those passing the P.Value and the false discovery
rate (Q.Value) of the test, the analysis continued with candidate genes in
Tumor samples only (blue area). The expression heterogeneity level of the
final selected gene is computed using MATH method (see Section 3.5.1).
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After classifying the cohort generally into two categories the downstream
analysis depicted in Figure 4.14 was followed. The given results came only
from two approaches: mutational bias (Oncodrive-FM), and genes covariates
(MutSigCV). Spatial clustering (Oncodrive-CLUSTER) did not report any sig-
nificant genes.
The three tools Oncodrive-FM, Oncodrive-CLUSTER, & MutSigCV were given
the list of genes G 1
2
and list of the mutations harbouring the genes (see Sec-
tion 3.4). From the significant genes, the set G1 was extracted. This assay
was followed to eliminate any source of bias while estimating the genes back-
ground pool. Surprisingly, the tool Oncodrive-CLUSTER did not report any
significant gene, therefore, in the following sections only the results coming
from the other tools were considered.
Likewise, in HRP the tools were given the list of genes G 1
2
and list of the
mutations harbouring the genes. The set G 1
2
was determined based on genes
mutated only in HRP.
The motivation behind this kind of approach is as follows:
1. Highlight potential Tumor specific genes.
2. Find whether having pair samples (Tumor and Tumor-free from same
patient) does change the results by comparing HRP with the entire
cohort, since obtaining Tfree tissue is not always possible.
4.3.2 Driver Genes: Initial Set
Figure 4.15 presents the amount of candidate genes reported by both tools
in RIBOLUTION cohort vs. HRP. Given that the group HRP consists of 16
patients only, the number of detected genes by both tools is plainly smaller
than the number of detected genes the whole Tumor samples.
Moreover, the genes pool is increased by including all genes that occur in at
least 50% of patients, therefore, it is expected to produce a large number of
potentially PCa associated genes (G 1
2
). Indeed, including genes which have
to be observed in all patients (G1) will notably decreases the nominated
genes.
As depicted in Figure 4.14, if the candidate genes in Tumor were found within
the candidate genes in non.Tumor they were filtered out.Therefore, in Figure
4.15 only the genes in the Tumor area (blue shaded) which where identified
by either tools or both (c) will be considered in the downstream analysis.
Thus, in RIBOLUTION cohort the potential PCa genes are the 228, while
in HRP are the 22.
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Entire Cohort HRP
(a) Oncodrive-FM
(b) MutSigCV
(c) Tools union
Figure 4.15: Number of candidate genes according to different approaches.
The original candidate list was filtered by P.value & Q.value (< 0.05; Q.value:
false discovery rate)). Displayed results were obtained from set G 1
2
(as ex-
plained in Figure 4.13), the genes in Tumor (c) are the ones used in the
downstream analysis. 66
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Entire Cohort HRP
G 1
2
G1
Figure 4.16: Final list of candidate.
Upper row, the 228 candidate genes mutated in at least 50% of the samples
(G 1
2
) in the entire cohort in comparison to HRP. The 15 genes identified
by both tools are: C4A, CALR, CENPN, EPS8L1, GFM1, GTF3A, HKR1,
LMOD1, NBR1, NWD1, SIX4, SWAP70, TTLL5, ZNF239, & ZNF93 (top
candidate genes). In HRP, none of the genes was detected by both tools,
the only gene identified by tool FM is SIM2. Moreover, none of these 15 genes
were found significantly mutated in the subgroup HRP. However, some of
the 21 genes in HRP were detected individually by the tools.
Lower row, significantly mutated genes in all patients G1, as previously ex-
plained the set G1 is a subset of G 1
2
. The only gene that was detected by
both tools is NWD1. In contrast, significantly mutated genes in HRP were
not found in the entire 16 patients G1. The highest occurrence in HRP was
seen in 12 patients (Tumor-Only) namely AMACR.
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As previously explained (Section 3.4), selecting candidate genes is based on
mutational functional impact and molecular state of the gene leading into
choosing 15 top candidate genes in RIBOLUTION , and 8 top candidate
genes in HRP. The sequence context of the SNV underlying their function
is shown in Figures 4.17 (the top candidate genes in RIBOLUTION ) and
4.18 (the detected candidate genes in HRP).
Figure 4.17: SNV s Effect within the top 15 candidate genes in the entire
cohort.
The columns in the upper, middle, and lower panels represent the patients
individually. Upper panel: mutational burden per patient, where non syn-
onymous variant are clrealy dominant. Left panel: percentage of patients
having the same gene mutated. Lower panel: different clinical data, where
darker colors indicates high value. Middle panel: the most deleterious SNV s
effect observed per patient (patients IDs were replaced by group name). In
the majority of genes, the missense effect is the highest malformed effect;
the effect is a subclass of non synonymous effect. The gene might have other
effects, only the highest is shown. NE : not exist, SNV s do not exist in the
gene for the particular patient.
All in all, between the subgroup HRP & RIBOLUTION there are 8 genes
which were detected as potential driver genes. However, none of these 8 genes
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were part of the 15 genes (Figure 4.16/RIBOLUTION .G 1
2
). These genes are
shown in Table 4.6.
Figure 4.18: Candidate genes in HRP-Tumor-Only.
Candidate Genes in HRP-TumorOnly reported by tool MutSigCV. None of
the candidate genes occur in the entire HRP-TumorOnly (16 patient). NE :
not exist, SNV s do not exist in the gene for the particular patient.
Another important test is to check the rest of genes which where significantly
mutated in one set but not in the other. From the 15 genes in the entire
RIBOLUTION cohort, only NWD1 was detected in the subgroup HRP as
well. However, it was found nearly significantly mutated according to one
method (P.value ∼ 0.06, significant if α < 0.1), namely SIFT (see Section
3.3.4.1). The gene NWD1 has yet unknown function. Speculations point
into its role in steady-state levels of Androgen receptor [36] (see Chapter 5
for further insights).
The final candidate genes were then chosen if they fulfil one of the following
criteria:
• if the gene was found in the merged cohort (Section 4.3.1) and in HRP,
• if the gene was detected by more than one tool within the merged
cohort or in HRP.
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Table 4.6: List of significantly mutated genes identified in the entire
cohort and in the subgroup HRP.
Gene HRPTool
Ribo.
Tool Gene
HRP
Tool
Ribo.
Tool
AMACR MutSigCV FM APEX1 MutSigCV
C12orf66 MutSigCV MutSigCV CEP55 MutSigCV
EPN3 MutSigCV MutSigCV IL20RA MutSigCV
MPP7 MutSigCV MutSigCV TNFRSF10A MutSigCV
4.4 Candidate Genes
In total, 23 genes were selected; Table 8.3 is a pair-wise mapping between
Gene’s ID and Gene’s symbol following Ensebml annotation. Figure 4.19
shows the candidate genes and their maximum mutational effect per patient.
In Table 4.7 the genes were sorted by their presence in the RIBOLUTION
cohort and summarized.
Figure 4.19: Final list of candidate genes.
Final list of candidate genes, in which missense variant is the most domi-
nant effect. Left panel indicates the percentage of patients having the gene
mutated. NE : not exist, SNV s do not exist in the gene for the particular
patient.
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4.4.1 Candidate Genes and its Heterogeneity
One crucial parameter in calling SNV s in RNA is its dependency on cells
population, which could be a source of hindrance in cancer, for heterogeneity
of Tumor could influence the SNV s identification. However, given that all
patients categorised under an elderly-onset cohort, their age makes them
from mutational prospective fall in the same bin. This is mainly why no
association between Age and other mutational parameters was found (Figure
4.10). Moreover, PCa is known to have no sever genomic alteration as in
other cancer types such as chronic myelogenous leukemia (CML). The later
explains the results in Table 4.8, in which, the amount of unique SNV s
each gene has was humble. Generally, candidate genes did not accumulate
large number of novel SNV s. On contrary, the majority did not have any
novel SNV , e.g. the known PCa biomarker AMACR has in total 6 SNV s.
These SNV s appear frequently between the patients (39) in the entire Tumor
samples, 5 are already reported in COSMIC to be associated with cancer,
and none of these 6 is novel. This observation is to be expected, since SNV s
in known biomarkers are formerly and comprehensively been studied. To
estimate the heterogeneity level of these genes MATH score (Mutations-Allele
Tumor Heterogeneity) is used as an indicator.
Table 4.8: Top candidate genes which have at least one novel SNV . The
column ]Patients shows number of patients in each subgroup, where each
patient has at least one novel SNV . The maximum effect of novel SNV s
is given. V:VLOW, L: LOW, M: MED, H: HIGH-Tumor . As a side note,
the novel SNV in gene TTLL5 was found in both Tumor and Tfree of
the same patient in HRP. Therefore, it is more likely that this SNV is
germline mutation, that this individual could have accumulated in his
life.
Gene ] SNV s Novel ] Patients Novel’s Effect
NWD1 13 1 1M Missense
C4A 8 5 2V, 1L, 1M, 3H 2× Missense,3× Synonymous
TTLL5 7 1 1H Stop lost
CALR 2 1 1H Missense
NBR1 4 1 1L Missense
GFM1 5 1 1M, 1H Synonymous
SWAP70 5 1 5V, 4L, 6M, 10H Synonymous
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For the MATH score relies upon the number of SNV s in the gene per patient,
the few amount of unique SNV s in each gene reduces its precision. For the
candidate genes, the MATH score in every patient was computed as depicted
in Figure 3.3, relying on the mutational allele fraction (see Section 3.5.1).
For these reasons, the interpretation of MATH score in RIBOLUTION rep-
resents different information. We believe MATH can give a good clue to the
allelic expression status. If MATH score was small, it is an indication that
the locus has expressed one allele more than the other, regardless of which
allele. While, high MATH indicates a fluctuation in the allelic expression.
Figure 4.20: MATH Score (Mutations-Allele Tumor Heterogeneity) of can-
didate genes.
For each subgroup in the entire cohort, MATH score of every candidate genes
was computed. The cut-off was set so that in every patient, the minimum
number of SNV s per gene = 5 , thus, only two out of the 23 genes passed this
relatively strict filter. A thin line is a single value which is estimated from
one patient (the only one that had enough number of SNV s). Therefore,
single values could be ignored (detailed heatmaps per patient is given in
the Supplementary 7.2.2 ). A clear allelic fluctuation can be seen in HIGH-
Tumor .
In Figure 4.20 the minimum number of SNV s is chosen to be 5 . For every
patient to have at least 5 mutation in the gene might not be the case, keeping
in mind that this study was restricted to the coding parts of the gene. The
cut-off of the SNV ’s number was also reduced to to 3 (Figure 4.21) and 4
(Figure 7.7).
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Seeing a variation in MATH score between the subgroups indicates the status
of the gene in that subgroup and accordingly the expressed allele. Since thin
line represents single value and therefore it is ignored for statistical reason,
this leave us with fewer subgroups to compare. Generally, a fluctuation in
the score suggests that both alleles were expressed, the higher the value is the
broader the distribution of allelic expression, i.e. the locus is not mono-allelic
expressed.
Figure 4.21: MATH Score in the top candidate genes.
Minimum amount of SNV s per patient within the gene = 3. Some genes do
not have MATH score in every subgroups, e.g. the gene CENPN (Centromere
protein N) is seen only in HIGH-Tumor ; the gene is an intracellular protein
whose expression level changes in response to androgen in PCa [137].
4.4.2 Candidate Genes Annotations
As it has been given in Table 4.7, in summary, more than 50% of the top
candidate genes were previously reported as related to PCa; interestingly all
of the candidate genes were observed expressed in the prostate tissue and
some were reported to be differentially expressed between the healthy and
cancerous tissue (e.g. Calreticulin (CALR)). However, not all of them had
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a direct functionality that is related to the prostate. For example, only two
genes were found associated with sexual reproduction, namely: CALR and
TTLL5. In the meantime, gene CALR (Calreticulin) is the only gene found
to be involved in hormone binding also in spermatogenesis, i.e. synthesis of
spermatozoa.
The main interest was in grouping the genes by additional properties when
it is possible. This sort of clustering is statistically not feasible due to the
small number of candidate genes. For these reasons, annotating the genes,
using GO annotation, is another way to highlight some of the cell activity
they are involved in. Measuring the enrichment of any biological function, on
the other hand, did not report any significant results between the candidate
genes. Generally, we annotated the genes using their Molecular Function and
the Biological Process 4.22.
(a) Biological Process (b) Molecular Function
Figure 4.22: GO Annotation of Candidate Genes in Tumor.
(a) the Biological Process and (b) the Molecular Function. In the figure, x-
axis shows total number of genes involved in the process. The process name
is given on y-axix. In (a) only biological process with at least 6 genes are
visualized. From the top candidate genes, at most 14 genes were involved
in different metabolic processes, while the rest were involved in other divers
process.
On molecular level, the genes are involved in protein binding. Notably, 4
genes were found involved in transcription factor activity; more specifically,
the three genes SIX4, ZNF239, ZNF93 which are involved in sequence-
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specific DNA binding (Figure 4.22.b). However, the functionality of members
in Zinc Finger protein family remains a speculation. Particularly, the gene
ZNF239 has undefined function. Gene ZNF93 on the other hand, is a known
repressor (negative regulation) [69].
Gene SIX4 (SIX Homeobox 4) acts as a transcriptional regulator according
to the pathway it is engaged in. SIX4 can also be involved in transcrip-
tional misregulation in cancer pathway. SNV s detected in this gene were
reported in hormone-related cancers (breast cancer) [152].
Additionally, gene APEX1 is found associated with different specific types of
cancers, such as attenuated familial adenomatous polyposis and intraocular
retinoblastoma [46,60,133].
For the most part, our novel candidate NWD1 is not annotated by any sort of
protein binding, instead, it was annotated in the same categories with GFM1,
SWAP70, SIX4, CALR, TTLL5, ZNF239, GTF3A, ZNF93, HKR1, APEX1,
namely: ion binding, organic cyclic compound binding, and heterocyclic com-
pound binding. Along with GFM1, SWAP70, & TTLL5 was annotated as
small molecule binding. Finally, annotated with GFM1, SWAP70, CALR,
& TTLL5 as carbohydrate derivative binding. The exact function of this
gene is unknown. Nonetheless, the SNV s detected in RIBOLUTION cohort
are already reported in COSMIC to be associated with large intestine and
endometrium.
4.5 More into HRP
Having a Tfree sample from the same patient can strengthen the analysis
and help build up our understanding to the PCa cohort. The main idea is to
test whether having such information benefit cancer studies especially when
analysing the mutations. The following sections summarize some of the main
observations. There’s an additional aspect of this, significant results remain
a hint and not conclusive, due to samples size.
4.5.1 Single Base Substitution Context
Single Base Substitution (SBS) is another term to describe single point mu-
tation. Knowing the exact nucleotide substitution aids the search to find
chemical differences within Tumor tissues in comparison to normal tissues
from the same organ. The absolute difference or exact difference presents in
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absolute numbers the difference between two data sets. However, the real
magnitude of the observed difference is given in percentage via relative differ-
ence. Figure 4.23 displays the observed SBS in all Tumor-Only samples and
Tfree-Only, the relative difference as given in Equation 4.3 was calculated.
RelativeDiff = TBSi − TfBSi
TfBSi
(4.3)
where:
TBSi : the quantity of observed SBS divided by the sum of all ob-
served SBSs in Tumor-Only | i ∈ {A− C,A−G, . . .}
TfBSi : similar to TBSi , yet, the observed SBS in Tfree-Only. The
Tfree-Only is considered the reference, as it is the closest form
to the tissues normal state.
The results in Figure 4.23.a do not fit into any of the signatures estimated in
the study [7]. Accordingly, observed signatures of PCa are mainly Signature
1A and Signature 6. Within the computed signatures, the SBS C > T is the
most dominant type observed in PCa, what is in RIBOLUTION cohort the
second dominant type.
To address the significance of the difference between Tumor-Only and Tfree-
Only samples, the test of significant proportion was applied, where H0 was
that the proportion of each SBS in both groups are not different. The test
reported the following base substitutions to be significant (P.V alue < 0.05):
Table 4.9: Test for SBS type. Comparing the quantative presence of
transversion once for the entire set of SNV s and second for the novel
ones only, in HRP.Tumor-Only vs. HRP.Tfree-Only. Assuming that
there is no difference between the chemical nature of Tumor samples and
Tfree samples, the null hypothesis (H0) states that both sets have the
same proportions of the chemical single base substitution (SBS). The
siginficatly small P.values decline H0.
Set Effect Ratio SNV s P-value
Tumor-Only Transversion 0.27 1.564e-05Tfree-Only 0.25
Novel Tumor-Only Transversion 0.06 1.293e-13Novel Tfree-Only 0.04
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(a) SBS Ratio in Tumor-Only
(b) SBS Ratio in Tfree-Only
(c) Relative Difference
Figure 4.23: Ratio of SBS in HRP sets.
(a) the ratio of observed SBS in HRP.Tumor-Only. (b) the ratio of observed
SBS in HRP.Tfree-Only. The ratio of each type is estimated with respect to
the total observation. (c) the relative difference between (a) and (b); positive
scores indicate over representation in Tumor samples while negative scores
are over representation in Tfree. The related difference was computed as in
Equation 4.3.
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4.5.2 Association With Clinical Parameters - HRP
Following the idea of testing whether having a pair samples would benefit
the analysis, testing the association with clinical data was done using the
Tumor-Only of the HRP.
Figure 4.24: Correlation of HRP.Tumor with clinical parameters.
The correlation between different parameters in the Tumor samples of HRP
(upper panel). The histogram of the different parameters for the set is given
in the diagonal panel. The lower panel shows the actual data and their
smoothing line. In total 16 patients were tested for the correlation using cor
function and method ”Pearson”.
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The association with different clinical factors with 16 patients is shown in
Figure 4.24. In which a positive correlation Tumor-Only mutations and the
amount of novel ones with none silent effect (missense). Notably, the value
of r is larger than the one estimated in case of the entire cohort.
This falls harmonically with a known idea that none silent SNV s are the
ones, that cancer acquire and preserve. While typical germline-events and
different SNV s, that the individual gather in his lifetime tend to be silent.
The later case was not filtered in the entire cohort, due to the lack of Tfree
samples.
The rest parameters did not show any significant association, it could be
because within the 16 patients the values are relatively alike. For example,
the patients have only two GS values (8,9).
4.6 Candidate Genes in HRP vs. Entire Co-
hort
Since HRP is the only subgroup that each individual has paired sam-
ples (Tumor, Tfree), it would be of particular interest to see the mutational
landscape in those vs. the entire cohort.
To convey the idea, the most two promising genes within the list of candidate
genes will be discussed, namely, the known PCa biomarker and drug target
AMACR as a prove of concept. Then, we discuss one of the potential players
in PCa, the NWD1 gene, we believe we are the first to report its potential
role in PCa solely from the mutational status of the gene.
4.6.1 AMACR - A Control Case
AMACR (alpha-methylacyl-CoA racemase) is an enzyme which is involved
in multiple cellular pathways, as in Lipid metabolism. AMACR has been
observed to be highly expressed in over 88% of PCa tissues in comparison to
normal prostate tissue [103], leading to believe that such observation is asso-
ciated with PCa. In consequence, anti-AMACR/P504S became a diagnostic
marker aiding needle biopsy.
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Figure 4.25: AMACR, the known PCa biomarker.
Upper plot: linearly arranged exons of the gene in RIBOLUTION cohort.
Most redundant SNV s between the 40 patients occur in Exon 1 (rs2278008,
chr5:33989518, 37 patients), and Exon 4 (rs2287939, chr5:33998883, 36
patients), despite their massive occurance clinical observations (clinVar
database) have ranked them as likely benign. However, the SNPs in
Exon 5 (rs10941112, chr5:34004707, 37 patients), and Exon 7 (rs3195676,
chr5:34008100, 31 patients) are confirmed somatic mutations in Melanomas
and Esophageal cancer [41, 179], and according to the predicting methods
used in this study they might have possible deleterious effect on protein
structure (SIFT & PPH2 ). Middle plot: likewise, the genomic position of
SNV s in HRP. The observed pile of patients (8) are all HRP after removing
shared SNV s and the SNV is also a known one (rs754140078,rs10472909,
chr5:33994116, 8 patients). In comparison to Tfree-Only (lower plot) none of
these SNV s occur in Tfree-Only except one SNV in one patient (rs10941112,
chr5:34004707), seeing this SNP in the Tfree-Only of the patient indicates
that the SNP was not present in the Tumor-Only of the same patient.
In the cohort, 6 unique SNV s were frequently reappearing between the pa-
tients (Figure 4.25). Out of these 6 SNV s 4 were reported in COSMIC in
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two cancer types, rhabdomyosarcoma carcinoma, and malignant melanoma;
2 were reported in another database (clinVar) to be possibly damaging. In-
terestingly, those particular two are very redundant between Tumor samples
(Figure 4.25, Exons 5 & 7) and according to the transcript they are in, the
likelihood of destroying the protein structure fluctuates (according to SIFT
& PPH2 ).
4.6.2 NWD1 - A Novel Observation
NWD1 drew our attention, because it was significantly mutated by different
methods and in different sets. NWD1 is the only gene that is present in the
entire Tumor samples (AMACR comes second, Figure 4.19). Additionally,
looking into the amount of SNV s, NWD1 was singled out to have the highest
number of unique detected SNV s (Figure 4.26), yet only one was a novel
SNV .
Figure 4.26: Unique SNV s in candidate genes vs. genes expression.
The log’s average of candidate genes expression level vs amount of SNV s. To
illustrate the amount of SNV s per gene, SNV s were filtered by their Genomic
Uniqueness (as given in see Section 4.1.8); this filter guarantees eliminating
any source of bias triggered by genes isoforms numbers. The average ex-
pression was estimated in the 40 Tumor-patients. No significant correlation
was found (using Pearson’s correlation), though, the association r was
positive.
Little is known about the exact function of NWD1, but it may play a role
in the control of androgen receptor (AR) protein steady-state levels [36].
Additionally, it tends to be up-regulated in prostate cancer in comparison to
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normal epithelium. Generally, the gene is highly expressed in testis, retina,
and trachea.
NWD1 was first identified in Zebrafish, in an attempt to address disease resis-
tance and immunity. Next, it was identified (orthologs) in mammalian [158].
Hence, it is annotated as a member of the NLR protein family (intracel-
lular Nucleotide-binding domain, Leucine rich repeat containing Receptors)
also called NOD-like receptors (Nucleotide binding Oligomerization Domain).
The family has over 20 members in human and over 30 in mice. Some of its
members are involved in number of intracellular processes such as apoptosis
and early development [84].
NWD1 consists of two main domains, NACHT and WD-repeat, hence the
name. The name NACHT stands for NAIP (neuronal apoptosis inhibitor pro-
tein), C2TA (MHC class 2 transcription activator), HET-E (incompatibility
locus protein from Podospora anserina) and TP1 (telomerase-associated pro-
tein. The domain has typical length of 300 to 400 residue, and was found in
animals, fungal and bacterial, making it highly evolutionary conserved pro-
tein domain. As the name indicates, NACHT domain is involved in major
histocompatibility complex (MHC ) and found in apoptosis proteins [81].
The WD-repeat domain, on the other hand, is typically 44-60 residue of
length which usually ends with the amino acid sequence tryptophan (W) –
aspartic acid (D). Additionally, most proteins with this domain contain at
least 7 WD-repeats copies. The protein family which WD-repeat is part of,
is considered a conservative protein family, the family’s size keeps expand-
ing [97,154].
The family of WD-repeat has crucial roles in many fundamental cellular activ-
ities, such as signal transduction, transcription regulation, cell cycle control,
autophagy, and apoptosis.
To understand the mutational profile of NWD1, the genomic distribution of
the SNV s is shown in Figure 4.27. The gene has in total 13 SNV s, 5 of
them were found in other cancers (e.g. Endometrium). Comparing the same
type of SNV s visualization with HRP Tumor-Only and HRP Tfree-Only,
showed that SNV s in Exon 8 of the gene seem to be related to cancer, as it
is quantitatively present in the HRP Tumor-Only.
It is worth taking into consideration that all observed SNV s are missense,
i.e. a single change in the codon that lead to different amino acid but length
remains intact. Additionally, in COSMIC there are about 60 publications
that reported observing different SNV s in NWD1 in a collection of cancers.
Between the 13 SNV s in the RIBOLUTION cohort, 5 were found to be
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confirmed somatic mutations in COSMIC in different cancer types, these
are: upper aerodigestive tract, haematopoietic and lymphoid tissue, thyroid,
large intestine, and breast . Of note, from the whole set of identified SNV s
in RIBOLUTION cohort within this gene none was found in prostate tissue
(both carcinoma & adenoma). Finally, the accumulation of SNV s in Exon 8
(Figure 4.27) appears in the protein domain WD-reapeat of the gene.
Figure 4.27: The potential PCa player, NWD1.
Upper plot: linearly arranged exons of the gene in RIBOLUTION cohort.
Therefore, the maximum value is 40, e.g. the same SNV was observed in
the entire cohort as in Exon 15, most occurance SNV is easilly spot for it
is a known SNP (rs2608737, chr19:16789027). Middle plot: likelwise, the
genomic position of SNV s in HRP. Clearly, none of the SNV s occur in the
Tumor-Only of HRP was found in the entire subgroup (16 patient), for it is
Tumor-Only. At most, a SNV was seen in 7 patients (Exon 8), this score is
significantly high when compared to Tfree-Only (lower plot).
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5.1 Variants Analysis in RNA-Seq
Since 2008, next generation sequencing is becoming more feasible and
cheaper, making it a very desired technique in comparison to the already
costly existing ones. Analyzing RNA-Seq is yet an ongoing topic and par-
ticularly the variants analysis is under progress. Keeping in mind that most
established genetic methods are DNA basis, the true power of analyzing
variants on RNA-Seq level is massively underestimated and mistaken if not
neglected.
Whether it was inherited or was acquired during individual’s life, the DNA
variant represents the genomic message. However, RNA variant is what the
cell literally working with. The thing that makes RNA SNV s of particular
importance and meaning. However, the lack of DNA makes it challeng-
ing to discriminate between the two cases. Hence, in this study identifying
germlines who turned into driver SNV s was not plausible. Instead, analyzing
functional facets is the most suitable, explainable and interpretable way to
work with variants on RNA-Seq.
5.1.1 The RIBOLUTION Cohort
Working with clinical data has its price. In the following section, the main
limitations are discussed and its possible solution. It is worth mentioning,
that some of these limitations contradicts with some fundamental aspects,
that makes it impossible to overcome or reverse.
For instance, despite being a relatively large cohort (48 samples including the
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control), when it comes to genetic questions, the fact that the whole patients
were RNA sequenced, makes it impossible to address many known aspects,
for example:
• Estimating HWL disruptive
• Distinguishing between imprinted genes, loss of heterogeneity (LOH),
and mono-expressed genes.
Moreover, due to the nature and location of the prostate gland, the control
does not convey healthy tissue, instead it comes from abnormal prostate
tissue, as in benign prostatic hyperplasia (see Sections 1.1 and 1.1.1).
This fact could explain the similarity in the results between the control and
the rest of the subgroups in the cohort.
Statistically, the small size of each subgroup (see Table 3.1) adds an ad-
ditional challenge when trying to spot and validate any difference. This
particular point hindered addressing the difference within the subgroups. In-
stead, to get as much statistical power, the cohort was first split into two
main classes: the Tumor set and the non.Tumor. Tumor set consists of all
Tumor samples in the cohort (40), the non.Tumor set consists of any none
Tumor samples, this includes the control and the Tumor-free samples (24).
This part of the analysis benefits from several facts:
• Tumor samples are 40, which stabilizes correlation assays (Section
4.2.3).
• Aids driver genes detection twice: first, gives a more comprehensive
genes pool. Second: by comparing the results with the those coming
from HRP analysis confirms the detection in both sets.
• Being an elderly onset (age ≥ 53 yr.) patients age does not additionally
subdivide the cohort, an influencing issue in usual cancer-genetics study
[170].
Additional aspect will be discussed in more details in the following sections.
5.1.1.1 Available Matched Normal Sample
The second type of analysis was done to only one subgroup, namely the
HRP, for it is the only subgroup that each patient has a Tumor-free (Tfree).
After excluding possible germline events (shared SNV s in Figure 4.3 - Step
6) the SNV s in Tumor samples were referred to as Tumor-Only and Tfree
as Tfree-Only. The results were constantly compared with the entire cohort
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including the HRP before excluding the shared SNV s. The later was referred
to as HIGH-Tumor and HIGH-Tfree.
5.1.2 CVR Module
The CVR is a pipeline designed particularly to identify SNV s solely in
RNA. The pipeline might look similar to existing attempts [130]. However,
in concept there are many novel turns within in, for example:
• Filtering reads: to our best knowledge addressing Numts in RNA before
SNV s calling has never been done before.
• Taking the intersect between different variants callers instead of the
union (Step 3 in Figure 4.3). The outcome of applying this filter can
be clearly seen in Figure 4.4.
• Filtering SNV s according to their positions within the reads, what
might imitates in concept other approaches, but it differs in perfor-
mance and accomplishment (see Section 4.1.4 for further details).
• The module is applicable to any other data sets.
5.1.2.1 Limitations
Generally, the limitations of any variants calling approach solely in RNA
data is its dependency on the genes expression. In other words, if the gene
is down regulated or not expressed at all in the tissue, detecting any SNV
could result from using reads harbouring the adjacent loci; what is another
source of false positive SNV s.
An interesting scenario, when a SNV exists in the promoter region of the
gene, that turned the promoter into a powerful one leading to expressing it
at higher level than normal, or the other way around. Such scenario can not
be seen solely via RNA sequences.
Additionally, from technical prospective, mapping reads to the expressed
protein isoform is not trivial. It could be that the SNV exists within an
ORF that is shared between multiple isoforms of the same gene. Thus, the
incapability of addressing this detail, makes it very challenging to predict,
which isoform was first expressed and affected.
The following list highlights additional technical challenges when analysing
variants and particularly in RNA-Seq:
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Sequence mapping : it is well known that mapping sequences is full of
technical bugs (see Figures 8.2 & 8.3). Mapping reads with none refer-
ence allele to the reference has been proven to be an additional source of
bias, since mappers tend to favour reads with reference allele. Mapping
bias is a crucial factor for estimating expression specific allele (ESA).
Identifying CNV , STR and others : any type of genetic variation that
relies on reads accumulation and counting is by definition impossible
to detect solely in RNA.
Expression Specific Allele (ESA) : to learn about it, a phasing step
(find the chromosome copy on which the allele was observed) and then
genotyping (cell genetic make up, i.e. phenotypes acclamation) must
first be done. Without DNA, this assay can not be applied.
In the same context, lacking of DNA samples hinders confirming the
underlying status of the gene, triggering the following question:
Mono-allelic or Bi-allelic Variants? even if the locus was heterogenous,
the gene might be mono-expressed. Mono-expressed gene mean that
only one allele is expressed. This scenario could be of a great interest
to learn about the disease associated variants [153].
RNA editing : RNA editing is another form of variation that was gener-
ated by RNA polymerase typically during RNA processing. The term
RNA processing may include splicing, 5’ capping, but RNA editing is
not considered one of it, as it could lead to insertion or deletion or
base substitution. Very much like the former concepts, to determine
true RNA editing sites, DNA is required. However, since any observed
variation could be relevant to the cancer, filtering for published RNA
editing sites was neglected.
5.1.2.2 Improvements and Prospective
Focusing on the coding parts served as the first attempt to measure the
plausibly of the methods and the quality level of the results. The results
produced by the established CVR module show high sensitivity level. Over
80% of SNV s were found in other public databases and published studies.
This observation suggested the potential of extending CVR module to the
none coding parts of the genome, i.e. ncRNA. The extension would require
to remove two main filters, namely the CDS Only I, and the CDS Only II
filter. Testing for sequence conservation would then be a must, as the ma-
jority classes of ncRNA is known to be poorly conserved on sequence level.
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Therefore, the filters need more tolerating adjustment, to consider the nature
of these regions.
From the prospective of SNV s annotation, since RNA structure in non cod-
ing regions is believed to be functionally related, predicting the SNV s effect
on the RNA secondary structure.
Generally, analyzing DNA based samples with the current version of CVR
module is possible and unproblematic. Supposing that paired samples (Tu-
mor and Tfree) were also provided then the following two main changes are
recommended:
1. replacing the SNV s callers by typical cancer specific ones. As a recom-
mendation both tools VarScan2 & Mutect are considered on the top
of the list for their sensitivity and specificity [29,80].
2. Step 6 in the module is not anymore required.
5.2 Candidate Genes
The final list of candidate genes have in common general cellular path-
ways, e.g. single-organism cellular process, cell regulation, and organic sub-
stance metabolic process. The level of association with PCa or with other
cancer types deviate between them, nonetheless. Therefore, whenever it is
known, additional information regarding particular association with male’s
reproductive system was given.
Among candidate genes, over 50% of the genes are PCa associated genes
(13/23) according to current studies. For instance, the genes AMACR & C4A
interact with prostate antigen complexes (Table 4.7). The association with
PCa of our candidate genes were roughly divided into three kinds according
to published studies:
• Up-Regulated: SWAP70, C4A, CEP55, NWD1, AMACR, CALR, &
CENPN.
• Cancer Related Signaling Pathway: EPS8L1, TNFRSF10A, IL20RA,
& MPP7.
• SNV s associated with PCa: TNFRSF10A, & APEX1.
91
Chapter 5. Discussion
5.2.1 Known and Potential Biomarkers
We also noticed that some of the candidate genes were solely detected in our
cohort to be potentially associated with PCa (5/23), referred to as First in
PCa via SNVs in Table 4.7. The only available information related to PCa is
the expression level, that could be seen in http://www.proteinatlas.org/
cancer and the degree of the confidence. These genes are: GFM1, NBR1,
GTF3A, EPN3, & LMOD1. These genes occur mostly in 20 patients and all
detected SNV s in these genes are known SNPs except for GFM1 & NBR1, in
which only one novel was detected. The genes have been addressed in other
types of cancer and their role have been already revealed, studies have earlier
suggested them as a potential biomarker, e.g. EPN3. This information could
be taken as a confirming hint, that the novel findings in this study could play
role in PCa as other studies suggested. Nevertheless, further research would
unveil the true nature of this potential association.
Notably, only three of the candidate genes were found in ICGC-UK, namely:
NWD1, SIX4, & TTLL5, while none of the candidate genes were found
in ICGC-DE (Figure 4.11.a). An explanation for this could be due to (1)
different sample size (ICGC-DE: 11 patients) and (2) different age category.
The RIBOLUTION cohort consists of elderly men, in which average age is
middle 60, while average age in ICGC-DE is estimated to be middle 50. Age
factor in PCa has been shown to change the mutational profile [170].
AMACR remains one of the well studied PCa biomarker. Figure 5.1 il-
lustrates known protein interaction network predicted by tool STRING. The
nodes are the proteins, and the edges represent the predicted functional as-
sociations. In this case, the thickness of the edge reflects the degree of pre-
diction confidence of the interaction. The genes seen in the Figure could be
arranged after their biological function. For example, ACOX1, ACOX2 and
ACOX3 are involved in the pathway peroxisomal fatty acid beta-oxidation,
which is part of Lipid metabolism. The genes OR51E1 and OR51E2 alter-
natively called PSGR (Prostate-specific G-protein coupled receptor/2) both
are located in cell membrane and Multi-pass membrane protein. Other genes
have their own unique function, gene KRT7 blocks the interferon-dependent
interphase and stimulates DNA synthesis in cells.
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Figure 5.1: AMACR’s protein interaction network.
The network was predicted by tool STRING and it summarizes the network
of predicted associations between AMACR and other genes. The nodes are
the proteins names while the edges represent protein-protein associations.
Arrow direction shows the action effects (positive: ., negative: a, unspec-
ified: ◦ ). The association with Androgen Receptor (AR) and Specificity
Protein 1 transcription factor (SP1 ) have high confidence association based
on text-mining. Besides text-mining the association with SP1 was due to
being a neighboring gene to AMACR. On the other hand, the direct associ-
ation between SP1 and AR was experimentally determined, the fourth edge
between these two indicates a binding action. Same type of edge connects
OR51E1 and OR51E2 (Olfactory receptor family 51 subfamily E member
1/2).
Another association with SP1 can be seen, a transcription factor that can
activate or repress transcription in response to physiological and patholog-
ical stimuli. Clearly this gene is involved with androgen receptor signaling
pathway, AR. The androgen receptor is a nuclear receptor that is activated
by binding the androgenic hormones, testosterone, or dihydrotestosterone in
the cytoplasm and then translocating the result into the nucleus.
The predicted network for gene NWD1, on the other hand, does not show any
positive, negative, or unspecified effect between any of the predicted genes
(Figure 5.2). The association with the three genes were predicted with high
confidence following text-mining, gene co-occurrence, curated databases, and
protein homology. All were not observed in [36], however. The same study
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has tested in vitro about 20 genes as NWD1 -related hits, which were not
predicted by STRING. This variation could be due to the fact that NWD1
is relatively a new gene, and its functionality in human yet to be understood.
Figure 5.2: NWD1 ’s proteins interaction network.
Edges represent protein-protein associations. The predicted functional part-
ner TEX10 ( testis-expressed sequence 10 protein) is involved in chromatin
binding as a molecular function. A coexpression with NWD1 was observed
in othe organisms but not in human. Moreover, the type of association be-
tween NWD1 and TEX10 is predicted to binding. UBE2V/2 : Ubiquitin
conjugating enzyme E2 V1/2, the genes involved in many cellular activi-
ties and biological processes, such as protein modification, proteolysis, T cell
receptor signaling pathway, & regulation of DNA repair.
5.3 AH and MATH Score in RNA-Seq
The AH is a meaningful indication to the Tumor underlying status. On
DNA level an approximation of sub-colonies within Tumor could be estimated
as followed in MATH score (see Section 4.4.1). However, on RNA level it
could be an indication of the alleles heterogeneity status.
One example for RNA-specific source of heterogeneity is Autosomal SNV s.
In diploid organism, when the SNV s are located on the sex chromosomes
(allosome) the expression level of its alleles would be a subject to sex dosage
compensation. The autosomal SNV s, on the other hand, do not need such a
process Therefore, it has been believed the autosomal SNV s would have their
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both alleles equally expressed. However, observations impugned this believe
and provided evidences that alleles are unevenly expressed [100,132,153].
Using the MATH score to substitute the infeasible former assays (Section
5.1.2.1) could then elaborate in multiple patients, typically per subgroup,
whether the locus of the gene is most likely heterogeneous. However, the
true status of the gene have been more trivial if DNA samples existed.
5.3.1 AH
In this study, Allelic Heterogeneity (AH ) refers to the proportion of none-
ref allele (Section 3.5.1). The distribution of AH has shown a skew towards
higher values (digonal panels in Figures 4.10 & 4.24). This observation means
that the detected mutations had their none-ref alleles more present than the
ref-allele instead of equally expressed alleles. An unequal expression level of
both alleles is a phenomena that has been seen in other studies [100,132,153].
The skewness in AH distribution has been observedin the subgroup HRP as
well. Zooming into deceased patients showed positive associations between
AH distribution and the amount of SNV s, novel SNV s, and missense effect.
However, none of these correlations was significant.
As a role of thump, testing for correlation is stable when the sample size
> 40, because lower sample size implies high standard error. These significant
results remain indications, for only larger cohort could confirm it.
5.3.2 MATH
MATH score was computed using three different cut-offs : 3,4 & 5 SNV s
in every patient (see Figures 4.21, 7.7, & 4.20). Keeping in mind that none
of the candidate genes were found significantly mutated in both non.Tumor
and the HRP-Tfree-Only sets. Interpreting MATH score as a score for het-
erozygous locus, revealed that only 6 genes had enough mutations, namely:
AMACR, CENPN, SWAP70, GFM1, GTF3A, & NWD1. The higher MATH
score is the wider the AH distribution is (Figure 3.3). I.e., both alleles were
expressed at different ratio, which certainly means that the gene is not mono-
allelic expressed, and therefore, could be assumed that none of the alleles was
preferred by the Tumor.
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6 Conclusion
In an attempt to find the plausibility of employing Single Nucleotide Variants
(SNV s) using solely RNA sequences in cancer data, the present study has
aimed to single out known and potential prostate cancer (PCa) players via
identifying SNV s and predicting its functionality.
SNV s are customarily identified on DNA level, consequently, available meth-
ods are originally designed to detect SNV s on DNA. Imposing upon these
methods to tolerate RNA sequences was one of the main challenges, which
has been emphasized throughout the study, starting from designing the right
approach till drawing the final conclusion.
Since the full functionality of the non-coding parts of the genome is yet to
be investigated, the impact of SNV s in non-coding regions is neither fully
understood nor precisely predicted. For these reasons, non-coding regions
were not included within the scope of this study. Though, we believe that
the proposed methods could be extended to include them with mindful cus-
tomization as discussed throughout the study.
After establishing RNA-friendly computational pipelines, SNV s were first
identified in the coding parts of the genome; then they were annotated by
their potential impact on every coding transcript for that gene. Obtaining
such information along with gene expression helped bringing further under-
standing to the genes they were found in. All of the identified candidate genes
has been reported previously by other studies, notably for their role in differ-
ent types of cancers and particularly in hormone-relate cancers. Yet, 22% of
the genes we observed to be significantly mutated in PCa we reported them
for the first time. Moreover, over 50% of the genes are reported to have di-
rect association with PCa, 2 of which are known PCa biomarkers. Therefore,
we conclude the plausibility of studying SNV s solely in RNA, as the results
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fall harmonically with the current knowledge. Of note, the newly observed
mutated genes in PCa could be of relevance to PCa diagnosis. Thus, further
analysis is required to confirm the exact role of these genes in PCa prognosis,
and the influence of inducing the identified SNV s on its functionality.
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7 Appendix A - Results
7.1 SNVs Annotation Summary
In this section a full summary provided by the tool VEP for the annotated
SNV s. The figures 7.1 and 7.2 represent the SNV s quantitative distribution
per chromosome.
CNTRL VLOW
LOW MED
Figure 7.1: SNVs by chromosome in the subgroups.
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HIGH-Tumor HIGH-Tumor.Only
HIGH-Tfree HIGH-Tfree.Only
HIGH.Shared
Figure 7.2: SNVs by chromosome in subgroup HRP.
Left panel: before removing shared SNV s in the individual (Step.6 in CVR
Module). Right panel: after controlling for shared SNV s.
After annotating the SNV s, the SNV s with an effect on the amino acid only
were kept (as explained in Section 4.2.2). The position of the SNV s in the
protein is shown in Figures 7.3 and 7.4.
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Figure 7.3: SNVs by their position in the protein in the subgroups.
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Figure 7.4: SNVs by their position in the protein in HRP.
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7.2 Candidate Genes
7.2.1 Expression Level of Candidate Genes
The expression level of the genes could contribute to the mutational quantity.
We find that the top candidate genes are not highly expressed, instead their
expression level falls within the average (a heatmap of expression level is
given in Figure 7.5). Prior the process of identifying candidate genes, the
expression level of the gene was taken as an additional parameter but not
the only one (Section 3.4.3).
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Figure 7.5: Expression Level of Candidate Genes.
The scale bar depicts the relative expression strength (red: high expression;
blue: low expression). Rows refer to genes name while columns were grouped
by the subgroup. Some of the genes in Tumor groups have clear different
expression pattern compared to none Tumor groups. Indeed, known PCa
biomarker AMACR can easily be singled out.
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Figure 7.6: Full list of the biological processes, in which the top candidate
genes are involved in. 105
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7.2.2 MATH Score of Candidate Genes
Figure 7.7: Mutations-Allele Tumor Heterogeneity score.
MATH Score (Mutations-Allele Tumor Heterogeneity) of candidate genes.
Minimum amount of SNV s per patient within the gene = 4, thus the majority
of candidate genes could not pass this cut-off. Interestingly, gene GFM1
appears only in non.Tumor set.
7.2.3 Mutational Landscape In Candidate Genes
The following Figures show how detected SNV s are distributed in the exons
of the candidate genes.
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APEX1
C4A
Figure 7.8: Mutational Landscape in Genes (APEX1, C4A)
Upper plot: linearly arranged exons of the gene in RIBOLUTION cohort.
Middle plot: likewise, the genomic position of SNV s in HRP. The lower plot
is Tfree-Only .
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C12orf66
CALR
Figure 7.9: Mutational Landscape in Genes (C12orf66, CALR)
Upper plot: linearly arranged exons of the gene in RIBOLUTION cohort.
Middle plot: likewise, the genomic position of SNV s in HRP. The lower plot
is Tfree-Only .
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CENPN
CEP55
Figure 7.10: Mutational Landscape in Genes (CENPN, CEP55)
Upper plot: linearly arranged exons of the gene in RIBOLUTION cohort.
Middle plot: likewise, the genomic position of SNV s in HRP. The lower plot
is Tfree-Only .
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EPN3
EPS8L1
Figure 7.11: Mutational Landscape in Genes (EPN3, EPS8L1)
Upper plot: linearly arranged exons of the gene in RIBOLUTION cohort.
Middle plot: likewise, the genomic position of SNV s in HRP. The lower plot
is Tfree-Only .
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GFM1
GTF3A
Figure 7.12: Mutational Landscape in Genes (GFM1, GTF3A)
Upper plot: linearly arranged exons of the gene in RIBOLUTION cohort.
Middle plot: likewise, the genomic position of SNV s in HRP. The lower plot
is Tfree-Only .
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HKR1
IL20RA
Figure 7.13: Mutational Landscape in Genes (HKR1, IL20RA)
Upper plot: linearly arranged exons of the gene in RIBOLUTION cohort.
Middle plot: likewise, the genomic position of SNV s in HRP. The lower plot
is Tfree-Only .
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LMOD1
MPP7
Figure 7.14: Mutational Landscape in Genes (LMOD1, MPP7)
Upper plot: linearly arranged exons of the gene in RIBOLUTION cohort.
Middle plot: likewise, the genomic position of SNV s in HRP. The lower plot
is Tfree-Only .
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NBR1
SIX4
Figure 7.15: Mutational Landscape in Genes (NBR1, SIX4)
Upper plot: linearly arranged exons of the gene in RIBOLUTION cohort.
Middle plot: likewise, the genomic position of SNV s in HRP. The lower plot
is Tfree-Only .
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SWAP70
TNFRSF10A
Figure 7.16: Mutational Landscape in Genes (SWAP70, TNFRSF10A)
Upper plot: linearly arranged exons of the gene in RIBOLUTION cohort.
Middle plot: likewise, the genomic position of SNV s in HRP. The lower plot
is Tfree-Only .
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TTLL5
ZNF93
Figure 7.17: Mutational Landscape in Genes (TTLL5, ZNF93)
Upper plot: linearly arranged exons of the gene in RIBOLUTION cohort.
Middle plot: likewise, the genomic position of SNV s in HRP. The lower plot
is Tfree-Only .
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Figure 7.18: ZNF239.
7.3 Clinical and Mutational Summary
In this section additional characteristics of the main will be provided. These
are believed to have an additional insights into the type of SNV s. Table 7.1
is the summary of clinical data for the 48 patients in the cohort.
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8.1 RNA-Seq
NGS is the improvement of the previous technology (e.g. Sanger sequenc-
ing), as it is cheaper, faster, and needs less amount of initial DNA to begin
with. The core concept of NGS sequencing is multiple sequencing at once
via obtaining the resulted optical signals which is released as every base is
being added. Using Illumina, reads of typical 100 length was generated.
adapter-R1: AGATC GGAAG AGCAC ACGTC TGAAC TCCAG
TCAC ((INDEX)) ATCTC GTATG CCGTC TTCTG
CTTG
adapter-R2: TCGGA AGAGC GTCGT GTAGG GAAAG AGTGT
AGAT CTCGG TGGTC GCCGT ATCATT
8.2 The CVR Module - Commands
In this section, the actual commands to run every step is given with its
parameters. The parameters explanation of each tool is generally not given,
as it could be found in the tools manual, website, or the associated reference.
However, occasionally the explanation is given if it helps clarifying the results.
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8.2.1 Step 1: Reads Filtering
The tracks of known annotations were first obtained, tracks complement is
computed, then only reads overlapping the complements are kept. These
steps were done using a collection of tools: Galaxy [52], Samtools and Bed-
tools/0.1.19 [95].
Repeat Masker :
The repetitive elements were obtained from http://genome-euro.ucsc.
edu, assembly:hg19/GRCH37, group:Repeats, and track:RepeatMasker,
then using Galaxy (https://usegalaxy.org/) the complimentary in-
tervals to these tracks were generated using the function Complement
intervals of a dataset (Galaxy Version 1.0.0). The generated
tracks were then given to intersect from the suite bedtools to remove
the reads that do not fall in the given regions.
Pseudogenes & Numts :
The Pseudogene were obtained from The Human GENCODE Gene
Set - Release: GRCH37 (http://www.gencodegenes.org/). The track
was obtained from http://www.gencodegenes.org/, assembly:hg19/GRCH37,
group:Variation.
Complement and intersect were generated likewise.
CDS :
CDS regions were extracted from the same GENCODE release using
the linux commands grep & awk. The CDS were also filtered so that
they do not overlap pseudogenes.
8.2.2 Step 2: Variants Calling - Best Practice
In the following section the commands used to apply the best practice of
calling variants are briefly given. Only last step was done twice, once with
samtools and second with GATK.
BAM Files Preparation
BAM files were validated and sorted using PICARD suite (Picard/1.118 [174]).
The sorting type was chosen to be coordinate sorted, because duplicate
reads mapping can take either coordinate-sorted or query-sorted inputs, how-
ever its behaviour differs slightly.
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Sorting was followed by adding group information, with the parameters:
AddOrReplaceReadGroups.jar LB = ScriptSeq \
PL = ILLUMINA PU = Kit SM = PCa
The paired end mate information were then fixed and the index was created.
Mark Duplicate Reads
Finally, duplicate reads were marked also using a sup-program in PICARD
suite, MarkDuplicates.jar with the parameters METRICS FILE = metrics
and VALIDATION STRINGENCY = LENIENT. The given reference in this step is
the human genome 19 (hg19).
INDELs
INDELs were specially handled using GATK suite. Given that the data are
RNA-seq, a special filter was applied in all of the coming procedures, namely
the filter reads with N cigar. The INDELs special treatment includes
(1) Creating a table of possible INDELs (2) Reads realignment around de-
tected possible INDELs.
Quality score recalibration
The final step before calling variants is to reassign base quality score. The
step is called Quality score recalibration, because every base was given a
quality score by the sequence mapper. Nonetheless after applying all previous
step it is necessary to correct this score to minimize false discovery calls. The
sub-program BaseRecalibrator in GATK suite was used.
Variations identification
GATK
The sub-program HaplotypeCaller was used to produce raw variations (ini-
tial call) with minimum filtering steps. The SNV s were called with the
parameters -stand call conf 50.0 and -stand emit conf 10.0
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Samtools
The identification of variants was using sub-program mpileup with parameter
-Q10. The VCF file was then generated via bcftools.
8.2.3 Steps 3, 4, 5, and 6
Using R, a collection of scripts were written to do the different tasks.
Figure 8.1 illustrates the underlying scripts of the CVR Module.
Figure 8.1: Scripts within CVR Module.
Some of the main scripts which were used to execute the main steps in
CVR Module. Squares with dashed lines are scripts written with R, while
tools and LINUX kernel commands are sketched by solid line. The script
Filter Falsfied Sites.R is used to filter dubious sites (Step 4, a,b, &
c). This script is executed twice as the input parameters differ, with/out
reference CDS intervals.
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8.2.4 Observed False Discoveries
In this section some of the main false discovered mutations are explained.
The majority of considered false discovered mutations were mainly induced
by SNP callers or reads mapper. Figure 8.2 shows a clear case of wrong
decision done by the SNP caller, as it has considered the short intron intervals
to be sequence deletion.
Figure 8.2: False discovered INDELs
Detected INDELs by GATK , a clear example of false positive calls induced by
the SNP caller. GATK has taken the introns to be deleted regions, especially
that the introns intervals are short. These INDELs did not pass the filters
in CVR Module.
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Figure 8.3, on the other hand, shows a technical error rather than wrong
decision. One possible cause for this behaviour is fact that the SNP caller
applies a local sequence alignment. At this stage, it is not clear whether the
shown short INDELs, SNV s and gapes were induced by the SNP caller or
initially awfully mapped by the sequence mapper (Segemehl).
Figure 8.3: False Positive Discovered INDEL
This INDEL is provoked by the SNP caller as a consequence from imprecise
mapping to the whole region. It has escaped the filtering for three reasons:
1) it is placed far from reads edges. 2) It is within 2 bp from the annotation.
3) The length of it is only 7 (GAACTTC). Section 4.1.4 gives in details the
filters and their cut-offs.
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8.3 Variants Annotating
8.3.1 SNPEff & SNPSift
Firstly, the chromosome should be only numeric :
perl -pe ’s/chr//’ infile > outfile
Running SNPEff :
java -Xmx4g -jar snpEff.jar -nodownload GRCh37.75 -c snpEff.config
infile > file.anno
Running SNPSift :
java -Xmx4g -jar SnpSift.jar extractFields -v -s "," -e "."
file.anno CHROM POS ID REF ALT QUAL FILTER
"ANN[*].GENE" "ANN[*].FEATURE" "ANN[*].FEATUREID"
"ANN[*].IMPACT" "ANN[*].EFFECT" "ANN[*].HGVS P"
"ANN[*].HGVS C" "ANN[*].RANK" "ANN[*].DISTANCE" > outfile
To annotate shared variants :
java -Xmx4g -jar snpEff.jar -nodownload GRCh37.75 -c snpEff.config
-cancer infile > outfile
where:
nodownload : if local database for snpEff does not exist do not download it.
c : path to configuration file
v : verbose mode
s : multiple field separator
e : replace empty fields with ’.’
cancer : compare cancerous variants vs. normal variants
extractFields: extract multiple values into separated fields
The rest of the fields indicate the value of the resulted prediction.
8.3.2 VEP
The mitochondrion chromosome is usually given by the SNPs callers as ’M’,
while VEP uses ’MT’ instead. Therefore, the first step is make sure the file
has the correct format:
perl -pe ’s/M/MT/’ infile > outfile
Running VEP with the following command:
perl variant effect predictor.pl -i infile --cache --force overwrite
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--fork 2 --sift b --polyphen b --port 3337 --symbol --gene phenotype
--pubmed --total length --numbers --domains --output file outfile
where:
Tools Performance Related Parameters
cache: enables locally fetching the required files of VEP, thus
VEP performance will be improved.
fork : enables forking to speed up the runtime of VEP.
port : define the database port manually. The value 3337
stands to the access port of the portal hosting GRCh37
v76 databases.
force overwrite : if the file is already existing it will be overwritten.
Variants Related Parameters
symbol : gene symbol will be added to the output (if available).
numbers : the number of exon and/or intron, where the variants
exists, is added the to output.
domains : adds names of protein domains overlapping that variant
position.
total length : adds the total length of CDS and protein positions as
follows Position/Length.
sift : ask VEP to print SIFT results along with the prediction,
b stands for both, numerically and predicts term.
polyphen : likewise, ask VEP to print the prediction of PPH2, b
stands for both, numerically and predicts term.
gene phenotype : print along with the results any known phenotype, dis-
ease or trait.
pubmed : print along with the results any known Pubmed IDs for
this cite.
8.3.3 Generation of Variants Summary
Biomart
mart < − useMart(’ENSEMBL MART ENSEMBL’,dataset="hsapiens gene ensembl",
host=’www.ensembl.org’)
results < − getBM(attributes = c(’ensembl gene id’, ’ensembl transcript id’,
’ensembl peptide id’), filters = ’ensembl transcript id’, values =
TRANSID, mart = mart )
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8.4 Driver Genes Identification
After SNV s annotation using VEP, a wrapping script (fromVEP 2Other.R)
is used, so that the files will fulfil the requirements of each tool in the down-
stream analysis, including visualization tools.
8.4.1 Oncodrive-Suite
The input of Oncodrive-Clust consists of the gene and it longest coding
transcript with the SNV s consequence and its position in the protein. The
tool also requires the SNV s to be split by their consequence into two ma-
jor categories: Non synonymous and synonymous. To determine the longest
transcript of each gene, the script Genes Trans Length 2OncodriveCLUST.R
was particularly written for this reason. The script takes GENCODE an-
notation for transcript, and computes the longest interval, the result, is a
table consists of the gene, transcript and its length. This table is then given
as an input to Oncodrive-Clust.
Oncodrive-FM, on the other hand, does not require the sequence consequence
of the SNV s, instead it takes as an input any other scoring parameter. In
this work, the scores assigned by SIFT & PPH2 to each SNV were given as an
input. Thus the input consisted on patient ID, gene, and two extra columns
for the scores given by each tool.
Oncodrive-Clust was then executed with the parameters m = 4, & coord.
For mutational bias, Oncodrive-FM was executed with the parameters N =
10000, gt = 4 & e = median.
where:
m minimum number of mutations to form a cluster
N number of simulation to compute the FM bias
e test estimator
gt minimum number of mutations per gene
coord to print cluster coordinates in the output file
8.4.2 Mutations Significant
MutSigCV requires matlab, the matlab’s version used in this study was v81.
MutSigCV was executed with the following parameters:
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File Usage
in file the mutations list was in MAF-format.
MutDic mutations dictionary which was created from RIBOLU-
TION cohort (see Tables 8.2 & 8.1)
exome full tab-delimited files which contains reference sequence of
human exome that breaks down by gene, categ, and
effect (Whole-exome capture libraries were constructed
and sequenced on Illumina HiSeq flowcells to an average
coverage of 118× [88]) .
gene covariates contains global expression of the gene estimated from
RIBOLUTION cohort, DNA replication time, & chro-
matin status.
The mutation dictionary is used to set up the categories needed by Mut-
SigCV. After filtering the mutations by CDS Only-II (see Section (3.2.1.1)),
the number of categories was reduced to the mentioned thirteen ones, where
? represents a case when VEP could not determine the effect. The DNA
effect categories recognized by MutSigCV are: null, silent, nonsilent, noncod-
ing. Those were chosen following the given definition in Sequence Ontology
(http://sequenceontology.org/index.html).
8.4.2.1 Reads Count
The gene count was computed using library(edgeR) patient-wise and genes
were kept only if their reads count was at least 3 in at least 4 patients. The
counts were estimated using function cpm; the function compromises between
large library size so genes with samll count will have to be thrown away, and
between counting per bases, were genes would seem higher expressed than
really are.
Then, the counts were normalized using function calcNormFactors. Finally,
the mean over all patients for each gene was taken . If the gene was not
expressed in RIBOLUTION cohort it will be then removed from the compu-
tation in MutSigCV, even if the called SNV s have effect on them possibly
due to adjacent genomic position.
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Table 8.1: Mutations Dictionary and Associated Score
Variant Classification effect Scale
Non Silent Variant
missense variant nonsilent 4
coding sequence variant nonsilent 4
start lost nonsilent 4
stop lost nonsilent 4
stop gained nonsilent 4
Non-Coding Variant
NMD transcript variant noncoding 3
intron variant noncoding 3
3 prime UTR variant noncoding 3
5 prime UTR variant noncoding 3
non coding transcript variant noncoding 3
non coding transcript exon variant noncoding 3
Silent Variant
synonymous variant silent 2
stop retained variant silent 2
Non ORF Variant
downstream gene variant null 1
upstream gene variant null 1
incomplete terminal codon variant null 1
splice acceptor variant null 1
splice donor variant null 1
splice region variant null 1
? Unknown 0
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8.5 Candidate Genes
Table 8.3: List of candidate genes and their IDs according to the standard
Ensembl annotation.
Symbol Full Name ID
AMACR Alpha-methylacyl-CoA racemase ENSG00000242110
APEX1 Apurinic/apyrimidinic endodeoxyri-
bonuclease 1
ENSG00000100823
C12orf66 Chromosome 12 open reading frame 66 ENSG00000174206
C4A Complement component 4A ENSG00000244731
CALR Calreticulin ENSG00000179218
CEP55 Centrosomal protein 55 ENSG00000138180
CENPN Centromere protein N ENSG00000166451
EPN3 Epsin 3 ENSG00000049283
EPS8L1 Epidermal growth factor receptor kinase
substrate 8-like protein 1
ENSG00000131037
GFM1 G elongation factor, mitochondrial 1 ENSG00000168827
GTF3A General transcription factor IIIA ENSG00000122034
HKR1 Krueppel-related zinc finger protein 1 ENSG00000181666
IL20RA Interleukin-20 receptor subunit alpha ENSG00000016402
LMOD1 Leiomodin-1 ENSG00000163431
MPP7 Membrane palmitoylated protein 7 ENSG00000150054
NBR1 Next to BRCA1 gene 1 protein ENSG00000188554
NWD1 NACHT and WD repeat domain con-
taining 1
ENSG00000188039
SIX4 Homeobox protein SIX4 ENSG00000100625
SWAP70 Switch-associated protein 70 ENSG00000133789
TNFRSF10A Tumor necrosis factor receptor super-
family member 10a
ENSG00000104689
TTLL5 Tubulin tyrosine ligase like 5 ENSG00000119685
ZNF239 Zinc finger protein 239 ENSG00000196793
ZNF93 Zinc finger protein 93 ENSG00000184635
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AH Allelic Heterogeneity. 36, 58, 92, 93, 130
BPH Benign Prostatic Hyperplasia. 2, 5, 9, 23, 42, 71–73, 79, 97, 130
CDS Coding Sequence. 17, 25, 42, 45, 47, 52, 115, 122, 123, 130
CNP Copy Number Polymorphism. 14, 130
CNV Copy Number Variations. 14, 86, 130
CVR Calling Variations in RNA-Seq, a proposed model to identify varia-
tions in solely transcriptomes data. 7, 8, 42, 45, 50, 51, 85, 130
DNA Deoxyribonucleic Acid. 1, 7, 11, 14, 20, 25, 26, 52, 53, 83, 86, 92, 94,
114, 123, 130
ESP NHLBI GO Exome Sequencing Project (ESP). http://evs.gs.washington.
edu/EVS/. 30, 130
EST Eastern Standard Time. 130
GATK Genome Analysis Toolkit. 28, 29, 45, 46, 116, 117, 130
GWAS Genome-wide association studys, http://www.gwascentral.org/.
53, 54, 130
HIGH-Tfree An abbreviation to the samples obtained from prostate tissue
of the same patient, where no cancer cells were detected, hence Tumor
free. The group HIGH is also referred to as HRP. HIGH is the only
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subgroup in which each patient has a a matching Tumor free samples
from the prostate tissue. 50, 130
HIGH-Tumor Tumor samples of the subgroup HIGH, the group is also
referred to as HRP. HIGH is the only subgroup in which each patient
has a a matching Tumor free samples from the prostate tissue. 50, 53,
59, 75, 82, 130
HRP High Risk Patients: patients with Gleason score > 7 and the only sub-
group that have Tumor free matched samples. Altogether, the group
consists of 16 patients, each with two samples from their prostate tis-
sue, i.e. 32 samples. vii, 24, 31, 44, 49, 50, 57, 64–73, 75, 77, 81, 82,
84, 88, 90–93, 130
HWL Hardy-Weinberg Law. 84, 130
INDEL Insertion or Deletion to number of nucleotides. vi, 25, 29, 30, 35,
44, 47–49, 51, 52, 57, 97–101, 116, 118, 119, 130
LD Linkage Disequilibrium. 130
Mb
bp 1
Kb 1,000
Mb 1,000,000 bp
Gb 1,000,000,000 bp
. 130
MHC Major Histocompatibility Complex: Set of cell surface proteins, which
the immune system needs to recognize foreign molecules (determines
histocompatibility). MHC molecules mediate interactions of leuko-
cytes, i.e. white blood cells (WBCs), with either leukocytes or other
body cells. To determine donor’s compatibility in organ transplant the
MHC is the key test.. 89, 130
mRNA messenger RNA is an RNA molecule that convey genetic informa-
tion after DNA transcription into the ribosome.. 11–13, 18, 19, 130
MSA Multiple Sequence Alignment. 32, 33, 130
ncRNA Non-coding RNA is a molecule that is not translated into a protein.
11, 130
Numts Nuclear mitochondrial sequences. 25, 45, 85, 130
ORF Open Reading Frame. 47, 85, 124, 130
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PCa Prostate Cancer. v, vii, 1–3, 5–9, 24, 42, 53, 54, 58, 60, 65, 71–75, 77,
79, 86, 87, 94, 129, 130
PCAV PCa Associated Variants. 53, 56, 130
Phred A Phred quality score is a measure of the quality of the identifi-
cation of the nucleobases generated by automated DNA sequencing.
Phred quality scores are assigned to each nucleotide base call in auto-
mated sequencer traces.[3][4] Phred quality scores have become widely
accepted to characterize the quality of DNA sequences, and can be used
to compare the efficacy of different sequencing methods. Perhaps the
most important use of Phred quality scores is the automatic determi-
nation of accurate, quality-based consensus sequences. 130
PPH2 Polymorphism Phenotyping v2: a method to predict variant evolu-
tionary effect from sequence and protein structure information.. 31,
33, 34, 87, 88, 130
PSA Prostate Specific Androgen. 1–4, 7, 58, 97–101, 130
RIBOLUTION Innovative Ribonucleic Acid-based Diagnostic Solutions for
Personalized Medicine. The cohort consists of 6 subgroups classified
jointly by Gleason Score and Lymphnode metastasis parameters.
V Very Low L Low
M* Medium (s: survived, d: death) HRP High Risk Patients
C Control pN indicates T + N classification
T Tumor Tf Tumor-free
Gleason Score GS < 7 GS = 7 GS ≤ 7 GS > 7 PCa.Free
Lymph Nodes
Metastasis
pN0 pN0 pN1 pN0 pN1 
Set VLOW(V) LOW(L) MED(Ms) MED(Md) HIGH Risk Patient(HRP) C
PSA 11 (SD ± 5.3) 8 (SD ± 4.2) 13 (SD ± 8.6) T: 29 (SD ± 55.6) 
Age (in year) 62 (SD ± 3) 65 (SD ± 3.8) 62 (SD ± 6.2) 63 (SD ± 6.4) 68 (SD ± 8)
Type T T T T T Tf T Tf T Tf T Tf 
Survival √ √ √ χ √ χ √ χ 
Sequenced 8 8 5 3 3 3 5 5 4 4 4 4 8
The clinical parameters of the RIBOLUTION cohort in details. v, vii,
1, 8, 9, 26, 42, 48, 52, 54, 55, 58–71, 75, 76, 79, 82, 84, 87, 88, 91, 94,
123, 127, 130
RNA Ribonucleic Acid. RNA is a polymeric molecule that is essential in the
cell for crucial biological function, such as regulation, gene’s expression,
and protein synthesis. Roughly, RNA could be divided into two major
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classes, namely the coding RNA and the non coding RNA.. 1, 7, 11,
12, 14, 19, 26, 42, 44, 45, 48, 83–86, 92, 94, 130
RNAP Is an enzyme that produces primary transcript RNA. RNAP is nec-
essary for constructing RNA chains using DNA genes as templates, a
process called transcription. RNA polymerase enzymes are essential to
life and are found in all organisms and many viruses. 11, 130
SBS
Single Base Substitution (SBS) is the
chemical nature of single point varia-
tion which is classified into transver-
sions and transition (blue and red
lines respectively in the figure). In
total, there are 6 different combina-
tions, which appear in 1:1 manner,
namely: Transversions (Tv) ∈ {A 
C,A  T,G  T,G  C}, and
Transition (Ti) ∈ {A  G, T  C}.
Figure was taken from [162].
. vi,
16, 30, 32, 33, 35, 79–81, 130
SIFT Sorting Tolerant From Intolerant Algorithm: a method to predict
variant evolutionary effect. 31–34, 69, 87, 88, 130
SMT Somatic Mutation Theory: The theory started around 1914, which
stated that mutations are the cause of cancer. The theory evolved
through the last century from one mutational hit to continuously ac-
cumulating mutations for the cancer to form. Additionally, it focuses
on the intra-cellular factors.. 130
SNP Single Nucleotide Polymorphism. 7, 14, 25, 29, 30, 53, 61, 87, 88, 91,
119, 121, 130
SNV Single Nucleotide Variants. v, vii, 1, 7, 8, 11, 14, 16–20, 26–28, 30,
31, 44–48, 50–58, 60, 61, 64, 68, 69, 74–79, 81–88, 90–92, 94, 97–101,
105, 107–113, 120, 127, 130
STR Short Tandem Repeats. 130
VEP Variants Effect Predictor: predicts position alteration in known tran-
scripts from sequence information.. 30, 33, 53, 123, 130
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